- Approval Id
- 10e6f4d833e265b5
- Drug Approval Emc Name
- Mirabegron Astellas 25 mg prolonged-release tablets
- Drug Name
- Mirabegron Astellas 25 mg prolonged-release tablets
- Company Name
- Astellas Pharma Ltd
- Company Address
- 300 Dashwood Lang Road, Bourne Business Park, Addlestone, KT15 2NX, UK
- Company Telephone
- +44 (0) 203 379 8700
- Company Medical Info Direct Line
- 0800 783 5018
- Company Medical Info Email
- medinfo.gb@astellas.com
- Company Stock Availability
- +44 (0) 203 379 8721
- Atc Code
- G04BD12
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Astellas Pharma Ltd.
300 Dashwood Lang Road
Bourne Business Park
Addlestone
United Kingdom
KT15 2NX
- Authorisation Number
- PLGB 00166/0415
PLGB 00166/0416
- Authorisation Date
- 01/01/2021
- Instruction Authorisation Holder
- Astellas Pharma Ltd.
300 Dashwood Lang Road
Bourne Business Park
Addlestone
United Kingdom
KT15 2NX
- Instruction Authorisation Number
- PLGB 00166/0415
PLGB 00166/0416
- Instruction Authorisation Date
- 01/01/2021
- Instruction Composition
- \*\*Mirabegron Astellas 25 mg prolonged-release tablets\*\*
Each tablet contains 25 mg of mirabegron.
\*\*Mirabegron Astellas 50 mg prolonged-release tablets\*\*
Each tablet contains 50 mg of mirabegron.
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Prolonged-release tablet.
\*\*Mirabegron Astellas 25 mg tablets\*\*
Oval, brown tablet, debossed with the company logo and “325” on the same side.
\*\*Mirabegron Astellas 50 mg tablets\*\*
Oval, yellow tablet, debossed with the company logo and “355” on the same side.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
\*\*Overactive bladder in adults\*\*
Mirabegron Astellas prolonged-release tablets are indicated for symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.
\*\*Neurogenic detrusor overactivity in the paediatric population\*\*
Mirabegron Astellas prolonged-release tablets are indicated for treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years.4.2 Posology and method of administration
\*\*Posology\*\*
\*\*\*Overactive bladder\*\*\*
\*Adults (including elderly patients)\*
The recommended dose is 50 mg once daily.
\*\*\*Neurogenic detrusor overactivity in the paediatric population\*\*\*
Paediatric patients 3 to less than 18 years of age with NDO may be administered Mirabegron Astellas prolonged-release tablets or Mirabegron Astellas granules for prolonged-release oral suspension based on the body weight of the patient. The prolonged-release tablets may be administered to patients weighing 35 kg or more; the granules for prolonged-release oral suspension are recommended for patients below 35 kg. Patients administered 6 ml oral suspension dose may be switched to 25 mg tablet dose and patients administered 10 ml oral suspension dose may be switched to 50 mg tablet dose.
The recommended starting dose of Mirabegron Astellas prolonged-release tablets is 25 mg once daily with food. If needed, the dose may be increased to a maximum dose of 50 mg once daily with food after 4 to 8 weeks. During long term therapy, patients should be periodically evaluated for treatment continuation and for potential dose adjustment, at least annually or more frequently if indicated.
Patients should be instructed to take any missed doses, unless more than 12 hours have passed since the missed dose. If more than 12 hours have passed, the missed dose can be skipped, and the next dose should be taken at the usual time.
\*\*Special populations\*\*
\*Renal and hepatic impairment\*
Mirabegron Astellas has not been studied in patients with end stage renal disease (ESRD) (estimated glomerular filtration rate (eGFR) < 15 ml/min/1.73 m2), patients requiring haemodialysis, or patients with severe hepatic impairment (Child-Pugh Class C) and, therefore, it is not recommended for use in these patient populations (see sections 4.4 and 5.2).
The following table provides the daily dosing recommendations for adult OAB patients with renal or hepatic impairment (see sections 4.4, 4.5 and 5.2).
\*\*Table 1: Daily dosing recommendations for adult OAB patients with renal or hepatic impairment\*\*
| | | |
| --- | --- | --- |
| \*\*Parameter\*\* | \*\*Classification\*\* | \*\*Dose\*\* \*\*(mg)\*\* |
| Renal impairment(1) | Mild/Moderate\\* | 50 |
| Severe\\*\\* | 25 |
| ESRD | Not recommended |
| Hepatic impairment(2) | Mild\\* | 50 |
| Moderate\\*\\* | 25 |
| Severe | Not recommended |
1. Mild/Moderate: eGFR 30 to 89 ml/min/1.73 m2; Severe: eGFR 15 to 29 ml/min/1.73 m2; ESRD: eGFR < 15 ml/min/1.73 m2.
2. Mild: Child-Pugh Class A; Moderate: Child-Pugh Class B; Severe: Child-Pugh Class C.
\\* In patients with mild to moderate renal impairment or mild hepatic impairment concomitantly receiving strong CYP3A inhibitors, the recommended dose is no more than 25 mg.
\\*\\* Not recommended for use in patients with severe renal impairment or moderate hepatic impairment concomitantly receiving strong CYP3A inhibitors.
The following table provides the daily dosing recommendations for paediatric NDO patients aged 3 to less than 18 years with renal or hepatic impairment weighing 35 kg or more (see sections 4.4 and 5.2).
\*\*Table 2: Daily dosing recommendations for paediatric NDO patients aged 3 to less than 18 years with renal or hepatic impairment weighing 35 kg or more\*\*
| | | | |
| --- | --- | --- | --- |
| \*\*Parameter\*\* | \*\*Classification\*\* | \*\*Starting dose\*\* \*\*(mg)\*\* | \*\*Maximum dose\*\* \*\*(mg)\*\* |
| Renal impairment(1) | Mild/Moderate\\* | 25 | 50 |
| Severe\\*\\* | 25 | 25 |
| ESRD | Not recommended | |
| Hepatic impairment(2) | Mild\\* | 25 | 50 |
| Moderate\\*\\* | 25 | 25 |
| Severe | Not recommended | |
1. Mild/Moderate: eGFR 30 to 89 ml/min/1.73 m2; Severe: eGFR 15 to 29 ml/min/1.73 m2;
ESRD: eGFR < 15 ml/min/1.73 m2. No dose adjustment is necessary for patients with mild to moderate renal impairment.
2. Mild: Child-Pugh Class A; Moderate: Child-Pugh Class B; Severe: Child-Pugh Class C.
\\* In patients with mild to moderate renal impairment or mild hepatic impairment concomitantly receiving strong CYP3A inhibitors, the recommended dose is no more than the starting dose.
\\*\\* Not recommended for use in patients with severe renal impairment or moderate hepatic impairment concomitantly receiving strong CYP3A inhibitors.
\*Gender\*
No dose adjustment is necessary according to gender.
\*Paediatric population\*
\*\*\*Overactive bladder\*\*\*
The safety and efficacy of mirabegron in children below 18 years of age with OAB have not yet been established. No data are available.
\*\*\*Neurogenic detrusor overactivity\*\*\*
The safety and efficacy of mirabegron in children below 3 years of age have not yet been established.
\*\*Method of administration\*\*
\*Overactive bladder in adults\*
The tablet is to be taken with liquids, swallowed whole, and is not to be chewed, divided, or crushed. It may be taken with or without food.
\*Neurogenic detrusor overactivity in the paediatric population\*
The tablet is to be taken with liquids, swallowed whole, and is not to be chewed, divided, or crushed. It should be taken with food.4.3 Contraindications
- Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
- Severe uncontrolled hypertension defined as systolic blood pressure ≥ 180 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg.4.4 Special warnings and precautions for use
\*\*Renal impairment\*\*
Mirabegron has not been studied in patients with ESRD (eGFR < 15 ml/min/1.73 m2) or patients requiring haemodialysis and, therefore, it is not recommended for use in this patient population. Data are limited in patients with severe renal impairment (eGFR 15 to 29 ml/min/1.73 m2); based on a pharmacokinetic study (see section 5.2) a dose of 25 mg once daily is recommended in this population. This medicinal product is not recommended for use in patients with severe renal impairment (eGFR 15 to 29 ml/min/1.73 m2) concomitantly receiving strong CYP3A inhibitors (see section 4.5).
\*\*Hepatic impairment\*\*
Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and, therefore, it is not recommended for use in this patient population. This medicinal product is not recommended for use in patients with moderate hepatic impairment (Child-Pugh B) concomitantly receiving strong CYP3A inhibitors (see section 4.5).
\*\*Hypertension\*\*
\*Overactive bladder in adults\*
Mirabegron can increase blood pressure. Blood pressure should be measured at baseline and periodically during treatment with mirabegron, especially in hypertensive patients.
Data are limited in patients with stage 2 hypertension (systolic blood pressure ≥ 160 mm Hg or diastolic blood pressure ≥ 100 mm Hg).
\*Neurogenic detrusor overactivity in the paediatric population\*
Mirabegron can increase blood pressure in paediatric patients. Blood pressure increases may be larger in children (3 to less than 12 years of age) than in adolescents (12 to less than 18 years of age). Blood pressure should be measured at baseline and periodically during treatment with mirabegron.
\*\*Patients with congenital or acquired QT prolongation\*\*
Mirabegron, at therapeutic doses, has not demonstrated clinically relevant QT prolongation in clinical studies (see section 5.1). However, since patients with a known history of QT prolongation or patients who are taking medicinal products known to prolong the QT interval were not included in these studies, the effects of mirabegron in these patients is unknown. Caution should be exercised when administering mirabegron in these patients.
\*\*Patients with bladder outlet obstruction and patients taking antimuscarinics medicinal products for OAB\*\*
Urinary retention in patients with bladder outlet obstruction (BOO) and in patients taking antimuscarinic medicinal products for the treatment of OAB has been reported in post‑marketing experience in patients taking mirabegron. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in patients treated with mirabegron; however, mirabegron should be administered with caution to patients with clinically significant BOO. Mirabegron should also be administered with caution to patients taking antimuscarinic medicinal products for the treatment of OAB.4.5 Interaction with other medicinal products and other forms of interaction
\*\*\*In vitro\* data\*\*
Mirabegron is transported and metabolised through multiple pathways. Mirabegron is a substrate for cytochrome P450 (CYP) 3A4, CYP2D6, butyrylcholinesterase, uridine diphospho‑glucuronosyltransferases (UGT), the efflux transporter P-glycoprotein (P-gp) and the influx organic cation transporters (OCT) OCT1, OCT2, and OCT3. Studies of mirabegron using human liver microsomes and recombinant human CYP enzymes showed that mirabegron is a moderate and time-dependent inhibitor of CYP2D6 and a weak inhibitor of CYP3A. Mirabegron inhibited P‑gp‑mediated drug transport at high concentrations.
\*\*\*In vivo\* data\*\*
\*Drug-drug interactions\*
The effect of co-administered medicinal products on the pharmacokinetics of mirabegron and the effect of mirabegron on the pharmacokinetics of other medicinal products was studied in single and multiple dose studies. Most drug‑drug interactions were studied using a dose of 100 mg mirabegron given as oral controlled absorption system (OCAS) tablets. Interaction studies of mirabegron with metoprolol and with metformin used mirabegron immediate‑release (IR) 160 mg.
Clinically relevant drug interactions between mirabegron and medicinal products that inhibit, induce or are a substrate for one of the CYP isozymes or transporters are not expected except for the inhibitory effect of mirabegron on the metabolism of CYP2D6 substrates.
\*Effect of enzyme inhibitors\*
Mirabegron exposure (AUC) was increased 1.8-fold in the presence of the strong inhibitor of CYP3A/P-gp ketoconazole in healthy volunteers. No dose-adjustment is needed when mirabegron is combined with inhibitors of CYP3A and/or P-gp. However, in patients with mild to moderate renal impairment (eGFR 30 to 89 ml/min/1.73 m2) or mild hepatic impairment (Child‑Pugh Class A) concomitantly receiving strong CYP3A inhibitors, such as itraconazole, ketoconazole, ritonavir and clarithromycin, the recommended dose is 25 mg once daily (see section 4.2). Mirabegron is not recommended in patients with severe renal impairment (eGFR 15 to 29 ml/min/1.73 m2) or patients with moderate hepatic impairment (Child‑Pugh Class B) concomitantly receiving strong CYP3A inhibitors (see sections 4.2 and 4.4).
\*Effect of enzyme inducers\*
Substances that are inducers of CYP3A or P-gp decrease the plasma concentrations of mirabegron. No dose adjustment is needed for mirabegron when administered with therapeutic doses of rifampicin or other CYP3A or P-gp inducers.
\*Effect of CYP2D6 polymorphism\*
CYP2D6 genetic polymorphism has minimal impact on the mean plasma exposure to mirabegron (see section 5.2). Interaction of mirabegron with a known CYP2D6 inhibitor is not expected and was not studied. No dose adjustment is needed for mirabegron when administered with CYP2D6 inhibitors or in patients who are CYP2D6 poor metabolisers.
\*Effect of mirabegron on CYP2D6 substrates\*
In healthy volunteers, the inhibitory potency of mirabegron towards CYP2D6 is moderate and the CYP2D6 activity recovers within 15 days after discontinuation of mirabegron. Multiple once daily dosing of mirabegron IR resulted in a 90% increase in Cmax and a 229% increase in AUC of a single dose of metoprolol. Multiple once daily dosing of mirabegron resulted in a 79% increase in Cmax and a 241% increase in AUC of a single dose of desipramine.
Caution is advised if mirabegron is co-administered with medicinal products with a narrow therapeutic index and significantly metabolised by CYP2D6, such as thioridazine, Type 1C antiarrhythmics (e.g., flecainide, propafenone) and tricyclic antidepressants (e.g., imipramine, desipramine). Caution is also advised if mirabegron is co-administered with CYP2D6 substrates that are individually dose titrated.
\*Effect of mirabegron on transporters\*
Mirabegron is a weak inhibitor of P-gp. Mirabegron increased Cmax and AUC by 29% and 27%, respectively, of the P-gp substrate digoxin in healthy volunteers. For patients who are initiating a combination of mirabegron and digoxin, the lowest dose for digoxin should be prescribed initially. Serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect. The potential for inhibition of P-gp by mirabegron should be considered when mirabegron is combined with sensitive P-gp substrates e.g. dabigatran.
\*Other interactions\*
No clinically relevant interactions have been observed when mirabegron was co-administered with therapeutic doses of solifenacin, tamsulosin, warfarin, metformin or a combined oral contraceptive medicinal product containing ethinylestradiol and levonorgestrel. Dose-adjustment is not recommended.
Increases in mirabegron exposure due to drug-drug interactions may be associated with increases in pulse rate.
\*\*Paediatric population\*\*
Interaction studies have only been performed in adults.4.6 Fertility, pregnancy and lactation
\*\*Women of childbearing potential\*\*
Mirabegron Astellas is not recommended in women of childbearing potential not using contraception.
\*\*Pregnancy\*\*
There are no or limited amount of data from the use of mirabegron in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Mirabegron Astellas is not recommended during pregnancy.
\*\*Breast-feeding\*\*
Mirabegron is excreted in the milk of rodents and therefore is predicted to be present in human milk (see section 5.3). No studies have been conducted to assess the impact of mirabegron on milk production in humans, its presence in human breast milk, or its effects on the breast-fed child.
Mirabegron Astellas should not be used during breast‑feeding.
\*\*Fertility\*\*
There were no treatment-related effects of mirabegron on fertility in animals (see section 5.3). The effect of mirabegron on human fertility has not been established.4.7 Effects on ability to drive and use machines
Mirabegron Astellas has no or negligible influence on the ability to drive and use machines.4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
The safety of mirabegron was evaluated in 8 433 adult patients with OAB, of which 5 648 received at least one dose of mirabegron in the phase 2/3 clinical program, and 622 patients received mirabegron for at least 1 year (365 days). In the three 12-week phase 3 double blind, placebo‑controlled studies, 88% of the patients completed treatment with this medicinal product, and 4% of the patients discontinued due to adverse events. Most adverse reactions were mild to moderate in severity.
The most common adverse reactions reported for adult patients treated with mirabegron 50 mg during the three 12-week phase 3 double blind, placebo-controlled studies are tachycardia and urinary tract infections. The frequency of tachycardia was 1.2% in patients receiving mirabegron 50 mg. Tachycardia led to discontinuation in 0.1% patients receiving mirabegron 50 mg. The frequency of urinary tract infections was 2.9% in patients receiving mirabegron 50 mg. Urinary tract infections led to discontinuation in none of the patients receiving mirabegron 50 mg. Serious adverse reactions included atrial fibrillation (0.2%).
Adverse reactions observed during the 1-year (long term) active controlled (muscarinic antagonist) study were similar in type and severity to those observed in the three 12-week phase 3 double blind, placebo‑controlled studies.
\*\*Tabulated list of adverse reactions\*\*
The table below reflects the adverse reactions observed with mirabegron in adults with OAB in the three 12-week phase 3 double blind, placebo‑controlled studies.
The frequency of adverse reactions is defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000) and not known (cannot be established from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
| | | | | | |
| --- | --- | --- | --- | --- | --- |
| \*\*MedDRA System organ class\*\* | \*\*Common\*\* | \*\*Uncommon\*\* | \*\*Rare\*\* | \*\*Very rare\*\* | \*\*Not known (cannot be estimated from the available data)\*\* |
| Infections and infestations | Urinary tract infection | Vaginal infection Cystitis | | | |
| Psychiatric disorders | | | | | Insomnia\\* Confusional state\\* |
| Nervous system disorders | Headache\\* Dizziness\\* | | | | |
| Eye disorders | | | Eyelid oedema | | |
| Cardiac disorders | Tachycardia | Palpitation Atrial fibrillation | | | |
| Vascular disorders | | | | Hypertensive crisis\\* | |
| Gastrointestinal disorders | Nausea\\* Constipation\\* Diarrhoea\\* | Dyspepsia Gastritis | Lip oedema | | |
| Hepatobiliary disorders | | GGT increased AST increased ALT increased | | | |
| Skin and subcutaneous tissue disorders | | Urticaria Rash Rash macular Rash papular Pruritus | Leukocytoclastic vasculitis Purpura Angioedema\\* | | |
| Musculoskeletal and connective tissue disorders | | Joint swelling | | | |
| Renal and urinary disorders | | | Urinary retention\\* | | |
| Reproductive system and breast disorders | | Vulvovaginal pruritus | | | |
| Investigations | | Blood pressure increased | | | |
\\*observed during post-marketing experience
\*\*Paediatric population\*\*
The safety of mirabegron tablets and oral suspension was evaluated in 86 paediatric patients aged 3 to less than 18 years with NDO in a 52-week, open-label, baseline-controlled, multicentre, dose titration study. The most commonly reported adverse reactions observed in the paediatric population were urinary tract infection, constipation, and nausea.
In the paediatric patients with NDO, no severe adverse reactions were reported.
Overall, the safety profile in children and adolescents is similar to that observed in adults.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Mirabegron has been administered to healthy adult volunteers at single doses up to 400 mg. At this dose, adverse events reported included palpitations (1 of 6 subjects) and increased pulse rate exceeding 100 beats per minute (bpm) (3 of 6 subjects). Multiple doses of mirabegron up to 300 mg daily for 10 days showed increases in pulse rate and systolic blood pressure when administered to healthy adult volunteers.
Treatment for overdose should be symptomatic and supportive. In the event of overdose, pulse rate, blood pressure, and ECG monitoring is recommended.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Urologicals, drugs for urinary frequency and incontinence, ATC code: G04BD12
\*\*Mechanism of action\*\*
Mirabegron is a potent and selective beta 3-adrenoceptor agonist. Mirabegron showed relaxation of bladder smooth muscle in rat and human isolated tissue, increased cyclic adenosine monophosphate (cAMP) concentrations in rat bladder tissue and showed a bladder relaxant effect in rat urinary bladder function models. Mirabegron increased mean voided volume per micturition and decreased the frequency of non-voiding contractions, without affecting voiding pressure, or residual urine in rat models of bladder overactivity. In a monkey model, mirabegron showed decreased voiding frequency. These results indicate that mirabegron enhances urine storage function by stimulating beta 3‑adrenoceptors in the bladder.
During the urine storage phase, when urine accumulates in the bladder, sympathetic nerve stimulation predominates. Noradrenaline is released from nerve terminals, leading predominantly to beta adrenoceptor activation in the bladder musculature, and hence bladder smooth muscle relaxation. During the urine voiding phase, the bladder is predominantly under parasympathetic nervous system control. Acetylcholine, released from pelvic nerve terminals, stimulates cholinergic M2 and M3 receptors, inducing bladder contraction. The activation of the M2 pathway also inhibits beta 3‑adrenoceptor induced increases in cAMP. Therefore, beta 3-adrenoceptor stimulation should not interfere with the voiding process. This was confirmed in rats with partial urethral obstruction, where mirabegron decreased the frequency of non-voiding contractions without affecting the voided volume per micturition, voiding pressure, or residual urine volume.
\*\*Pharmacodynamic effects\*\*
\*Urodynamics\*
Mirabegron at doses of 50 mg and 100 mg once daily for 12 weeks in men with lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) showed no effect on cystometry parameters and was safe and well tolerated. The effects of mirabegron on maximum flow rate and detrusor pressure at maximum flow rate were assessed in this urodynamic study consisting of 200 male patients with LUTS and BOO. Administration of mirabegron at doses of 50 mg and 100 mg once daily for 12 weeks did not adversely affect the maximum flow rate or detrusor pressure at maximum flow rate. In this study in male patients with LUTS/BOO, the adjusted mean (SE) change from baseline to end of treatment in post void residual volume (ml) was 0.55 (10.702), 17.89 (10.190), 30.77 (10.598) for the placebo, mirabegron 50 mg and mirabegron 100 mg treatment groups.
\*Effect on QT interval\*
Mirabegron at doses of 50 mg or 100 mg had no effect on the QT interval individually corrected for heart rate (QTcI interval) when evaluated either by sex or by the overall group.
A thorough QT (TQT) study (n=164 healthy male and n=153 healthy female volunteers with a mean age of 33 years) evaluated the effect of repeat oral dosing of mirabegron at the indicated dose (50 mg once daily) and two supra-therapeutic doses (100 and 200 mg once daily) on the QTcI interval. The supra-therapeutic doses represent approximately 2.6- and 6.5‑fold the exposure of the therapeutic dose, respectively. A single 400 mg dose of moxifloxacin was used as a positive control. Each dose level of mirabegron and moxifloxacin was evaluated in separate treatment arms each including placebo-control (parallel cross-over design). For both males and females administered mirabegron at 50 mg and 100 mg, the upper bound of the one-sided 95% confidence interval did not exceed 10 msec at any time point for the largest time-matched mean difference from placebo in the QTcI interval. In females administered mirabegron at the 50 mg dose, the mean difference from placebo on QTcI interval at 5 hours post dose was 3.67 msec (upper bound of the one-sided 95% CI 5.72 msec). In males, the difference was 2.89 msec (upper bound of the one-sided 95% CI 4.90 msec). At a mirabegron dose of 200 mg, the QTcI interval did not exceed 10 msec at any time point in males, while in females the upper bound of the one-sided 95% confidence interval did exceed 10 msec between 0.5–6 hours, with a maximum difference from placebo at 5 hours where the mean effect was 10.42 msec (upper bound of the one-sided 95% CI 13.44 msec). Results for QTcF and QTcIf were consistent with QTcI.
In this TQT study, mirabegron increased heart rate on ECG in a dose dependent manner across the 50 mg to 200 mg dose range examined. The maximum mean difference from placebo in heart rate ranged from 6.7 bpm with mirabegron 50 mg up to 17.3 bpm with mirabegron 200 mg in healthy subjects.
\*Effects on pulse rate and blood pressure in adult patients with OAB\*
In OAB patients (mean age of 59 years) across three 12-week phase 3 double blind, placebo‑controlled studies receiving mirabegron 50 mg once daily, an increase in mean difference from placebo of approximately 1 bpm for pulse rate and approximately 1 mm Hg or less in systolic blood pressure/diastolic blood pressure (SBP/DBP) was observed. Changes in pulse rate and blood pressure are reversible upon discontinuation of treatment.
\*Effects on blood pressure in paediatric patients with NDO\*
Mirabegron can increase blood pressure in paediatric patients. Blood pressure increases may be larger in children (3 to less than 12 years of age) than in adolescents (12 to less than 18 years of age). Blood pressure should be measured at baseline and periodically during treatment with mirabegron.
\*Effect on intraocular pressure (IOP)\*
Mirabegron 100 mg once daily did not increase IOP in healthy adult subjects after 56 days of treatment. In a phase 1 study assessing the effect of mirabegron on IOP using Goldmann applanation tonometry in 310 healthy subjects, a dose of mirabegron 100 mg was non-inferior to placebo for the primary endpoint of the treatment difference in mean change from baseline to day 56 in subject-average IOP; the upper bound of the two-sided 95% CI of the treatment difference between mirabegron 100 mg and placebo was 0.3 mm Hg.
\*\*Clinical efficacy and safety\*\*
\*Overactive bladder in adult patients\*
Efficacy of mirabegron was evaluated in three phase 3 randomised, double blind, placebo‑controlled, 12-week studies for the treatment of overactive bladder with symptoms of urgency and frequency with or without incontinence. Female (72%) and male (28%) patients with a mean age of 59 years (range 18 – 95 years) were included. The study population consisted of approximately 48% antimuscarinic treatment naïve patients as well as approximately 52% patients previously treated with antimuscarinic medicinal products. In one study, 495 patients received an active control (tolterodine prolonged release formulation).
The co-primary efficacy endpoints were (1) change from baseline to end of treatment in mean number of incontinence episodes per 24 hours and (2) change from baseline to end of treatment in mean number of micturitions per 24 hours based on a 3-day micturition diary. Mirabegron demonstrated statistically significant larger improvements compared to placebo for both co-primary endpoints as well as secondary endpoints (see Tables 3 and 4).
\*\*Table 3: Co-primary and selected secondary efficacy endpoints at end of treatment for pooled studies in adults\*\*
| | | |
| --- | --- | --- |
| \*\*Parameter\*\* | \*\*Pooled studies\*\* \*\*(046, 047, 074)\*\* | |
| \*\*Placebo\*\* | \*\*Mirabegron\*\* \*\*50 mg\*\* |
| \*\*Mean number of incontinence episodes per 24 hours (FAS‑I) (Co-primary)\*\* | | |
| n | 878 | 862 |
| Mean baseline | 2.73 | 2.71 |
| Mean change from baseline\\* | -1.10 | -1.49 |
| Mean difference from placebo\\* (95% CI) | -- | -0.40 (-0.58, -0.21) |
| p-value | -- | < 0.001‡ |
| \*\*Mean number of micturitions per 24 hours (FAS) (Co-primary)\*\* | | |
| n | 1 328 | 1 324 |
| Mean baseline | 11.58 | 11.70 |
| Mean change from baseline\\* | -1.20 | -1.75 |
| Mean difference from placebo\\* (95% CI) | -- | -0.55 (-0.75, -0.36) |
| p-value | -- | < 0.001‡ |
| \*\*Mean volume voided (ml) per micturition (FAS) (Secondary)\*\* | | |
| n | 1 328 | 1 322 |
| Mean baseline | 159.2 | 159.0 |
| Mean change from baseline\\* | 9.4 | 21.4 |
| Mean difference from placebo\\* (95% CI) | -- | 11.9 (8.3, 15.5) |
| p-value | -- | < 0.001‡ |
| \*\*Mean level of urgency (FAS) (Secondary)\*\* | | |
| n | 1 325 | 1 323 |
| Mean baseline | 2.39 | 2.42 |
| Mean change from baseline\\* | -0.15 | -0.26 |
| Mean difference from placebo\\* (95% CI) | -- | -0.11 (-0.16, -0.07) |
| p-value | -- | < 0.001‡ |
| \*\*Mean number of urgency incontinence episodes per 24 hours (FAS-I) (Secondary)\*\* | | |
| n | 858 | 834 |
| Mean baseline | 2.42 | 2.42 |
| Mean change from baseline\\* | -0.98 | -1.38 |
| Mean difference from placebo\\* (95% CI) | -- | -0.40 (-0.57, -0.23) |
| p-value | -- | < 0.001‡ |
| \*\*Mean number of episodes with urgency grades 3 or 4 per 24 hours (FAS) (Secondary)\*\* | | |
| n | 1 324 | 1 320 |
| Mean baseline | 5.61 | 5.80 |
| Mean change from baseline\\* | -1.29 | -1.93 |
| Mean difference from placebo\\* (95% CI) | -- | -0.64 (-0.89, -0.39) |
| p-value | -- | < 0.001‡ |
| \*\*Treatment satisfaction – visual analogue scale (FAS) (Secondary)\*\* | | |
| n | 1 195 | 1 189 |
| Mean baseline | 4.87 | 4.82 |
| Mean change from baseline\\* | 1.25 | 2.01 |
| Mean difference from placebo\\* (95% CI) | -- | 0.76 (0.52, 1.01) |
| p-value | -- | < 0.001† |
Pooled studies consisted of studies 046 (Europe/Australia), 047 (North America [NA]) and 074 (Europe/NA).
\\* Least squares mean adjusted for baseline, gender, and study.
† Statistically significantly superior compared to placebo at the 0.05 level without multiplicity adjustment.
‡ Statistically significantly superior compared to placebo at the 0.05 level with multiplicity adjustment.
FAS: Full analysis set, all randomised patients who took at least 1 dose of double blind study drug and who had a micturition measurement in the baseline diary and at least 1 post-baseline visit diary with a micturition measurement.
FAS-I: Subset of FAS who also had at least 1 incontinence episode in the baseline diary.
CI: Confidence Interval
\*\*Table 4: Co-primary and selected secondary efficacy endpoints at end of treatment for studies 046, 047 and 074 in adults\*\*
| | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| \*\*Parameter\*\* | \*\*Study 046\*\* | | | \*\*Study 047\*\* | | \*\*Study 074\*\* | |
| \*\*Placebo\*\* | \*\*Mirabegron 50 mg\*\* | \*\*Tolterodine ER 4 mg\*\* | \*\*Placebo\*\* | \*\*Mirabegron 50 mg\*\* | \*\*Placebo\*\* | \*\*Mirabegron 50 mg\*\* |
| \*\*Mean number of incontinence episodes per 24 hours (FAS‑I) (Co-primary)\*\* | | | | | | | |
| n | 291 | 293 | 300 | 325 | 312 | 262 | 257 |
| Mean baseline | 2.67 | 2.83 | 2.63 | 3.03 | 2.77 | 2.43 | 2.51 |
| Mean change from baseline\\* | -1.17 | -1.57 | -1.27 | -1.13 | -1.47 | -0.96 | -1.38 |
| Mean difference from placebo\\* | -- | -0.41 | -0.10 | -- | -0.34 | -- | -0.42 |
| 95% Confidence Interval | -- | (-0.72, ‑0.09) | (-0.42, 0.21) | -- | (-0.66, -0.03) | -- | (-0.76, -0.08) |
| p-value | -- | 0.003‡ | 0.11 | -- | 0.026‡ | -- | 0.001‡ |
| \*\*Mean number of micturitions per 24 hours (FAS) (Co-primary)\*\* | | | | | | | |
| n | 480 | 473 | 475 | 433 | 425 | 415 | 426 |
| Mean baseline | 11.71 | 11.65 | 11.55 | 11.51 | 11.80 | 11.48 | 11.66 |
| Mean change from baseline\\* | -1.34 | -1.93 | -1.59 | -1.05 | -1.66 | -1.18 | -1.60 |
| Mean difference from placebo\\* | -- | -0.60 | -0.25 | -- | -0.61 | -- | -0.42 |
| 95% Confidence Interval | -- | (-0.90, -0.29) | (-0.55, 0.06) | -- | (-0.98, -0.24) | -- | (-0.76, -0.08) |
| p-value | -- | < 0.001‡ | 0.11 | -- | 0.001‡ | -- | 0.015‡ |
| \*\*Mean volume voided (ml) per micturition (FAS) (Secondary)\*\* | | | | | | | |
| n | 480 | 472 | 475 | 433 | 424 | 415 | 426 |
| Mean baseline | 156.7 | 161.1 | 158.6 | 157.5 | 156.3 | 164.0 | 159.3 |
| Mean change from baseline\\* | 12.3 | 24.2 | 25.0 | 7.0 | 18.2 | 8.3 | 20.7 |
| Mean difference from placebo\\* | -- | 11.9 | 12.6 | -- | 11.1 | -- | 12.4 |
| 95% Confidence Interval | -- | (6.3, 17.4) | (7.1, 18.2) | -- | (4.4, 17.9) | -- | (6.3, 18.6) |
| p-value | -- | < 0.001‡ | < 0.001† | -- | 0.001‡ | -- | < 0.001‡ |
| \*\*Mean level of urgency (FAS) (Secondary)\*\* | | | | | | | |
| n | 480 | 472 | 473 | 432 | 425 | 413 | 426 |
| Mean baseline | 2.37 | 2.40 | 2.41 | 2.45 | 2.45 | 2.36 | 2.41 |
| Mean change from baseline\\* | -0.22 | -0.31 | -0.29 | -0.08 | -0.19 | -0.15 | -0.29 |
| Mean difference from placebo\\* | -- | -0.09 | -0.07 | -- | -0.11 | -- | -0.14 |
| 95% Confidence Interval | -- | (-0.17, -0.02) | (-0.15, 0.01) | -- | (-0.18, -0.04) | -- | (-0.22, -0.06) |
| p-value | -- | 0.018† | 0.085 | -- | 0.004† | -- | < 0.001§ |
| \*\*Mean number of urgency incontinence episodes per 24 hours (FAS-I) (Secondary)\*\* | | | | | | | |
| n | 283 | 286 | 289 | 319 | 297 | 256 | 251 |
| Mean baseline | 2.43 | 2.52 | 2.37 | 2.56 | 2.42 | 2.24 | 2.33 |
| Mean change from baseline\\* | -1.11 | -1.46 | -1.18 | -0.89 | -1.32 | -0.95 | -1.33 |
| Mean difference from placebo\\* | -- | -0.35 | -0.07 | -- | -0.43 | -- | -0.39 |
| 95% Confidence Interval | -- | (-0.65, -0.05) | (-0.38, 0.23) | -- | (-0.72, -0.15) | -- | (-0.69, -0.08) |
| p-value | -- | 0.003† | 0.26 | -- | 0.005† | -- | 0.002§ |
| \*\*Mean number of episodes with urgency grades 3 or 4 per 24 hours (FAS) (Secondary)\*\* | | | | | | | |
| n | 479 | 470 | 472 | 432 | 424 | 413 | 426 |
| Mean baseline | 5.78 | 5.72 | 5.79 | 5.61 | 5.90 | 5.42 | 5.80 |
| Mean change from baseline\\* | -1.65 | -2.25 | -2.07 | -0.82 | -1.57 | -1.35 | -1.94 |
| Mean difference from placebo\\* | -- | -0.60 | -0.42 | -- | -0.75 | -- | -0.59 |
| 95% Confidence Interval | -- | (-1.02, -0.18) | (-0.84, -0.00) | -- | (-1.20, -0.30) | -- | (-1.01, -0.16) |
| p-value | -- | 0.005† | 0.050† | -- | 0.001† | -- | 0.007§ |
| \*\*Treatment satisfaction – visual analogue scale (FAS) (Secondary)\*\* | | | | | | | |
| n | 428 | 414 | 425 | 390 | 387 | 377 | 388 |
| Mean baseline | 4.11 | 3.95 | 3.87 | 5.5 | 5.4 | 5.13 | 5.13 |
| Mean change from baseline\\* | 1.89 | 2.55 | 2.44 | 0.7 | 1.5 | 1.05 | 1.88 |
| Mean difference from placebo\\* | -- | 0.66 | 0.55 | -- | 0.8 | -- | 0.83 |
| 95% Confidence Interval | -- | (0.25, 1.07) | (0.14, 0.95) | -- | (0.4, 1.3) | -- | (0.41, 1.25) |
| p-value | -- | 0.001† | 0.008† | -- | < 0.001† | -- | < 0.001† |
\\* Least squares mean adjusted for baseline, gender and geographical region.
† Statistically significantly superior compared with placebo at the 0.05 level without multiplicity adjustment.
‡ Statistically significantly superior compared with placebo at the 0.05 level with multiplicity adjustment.
§ Not statistically significantly superior compared to placebo at the 0.05 level with multiplicity adjustment.
FAS: Full analysis set, all randomised patients who took at least 1 dose of double blind study drug and who had a micturition measurement in the baseline diary and at least 1 post-baseline visit diary with a micturition measurement.
FAS-I: Subset of FAS who also had at least 1 incontinence episode in the baseline diary.
Mirabegron 50 mg once daily was effective at the first measured time point of week 4, and efficacy was maintained throughout the 12-week treatment period. A randomised, active controlled, long term study demonstrated that efficacy was maintained throughout a 1-year treatment period.
\*Subjective improvement in health-related quality of life measurements\*
In the three 12-week phase 3 double blind, placebo‑controlled studies, treatment of the symptoms of OAB with mirabegron once daily resulted in a statistically significant improvement over placebo on the following health-related quality of life measures: treatment satisfaction and symptom bother.
\*Efficacy in patients with or without prior OAB antimuscarinic therapy\*
Efficacy was demonstrated in patients with and without prior OAB antimuscarinic therapy. In addition mirabegron showed efficacy in patients who previously discontinued OAB antimuscarinic therapy due to insufficient effect (see Table 5).
\*\*Table 5: Co-primary efficacy endpoints for adult patients with prior OAB antimuscarinic therapy\*\*
| | | | | | |
| --- | --- | --- | --- | --- | --- |
| \*\*Parameter\*\* | \*\*Pooled studies\*\* \*\*(046, 047, 074)\*\* | | \*\*Study 046\*\* | | |
| \*\*Placebo\*\* | \*\*Mirabegron 50 mg\*\* | \*\*Placebo\*\* | \*\*Mirabegron 50 mg\*\* | \*\*Tolterodine ER 4 mg\*\* |
| \*\*Patients with prior OAB antimuscarinic therapy\*\* | | | | | |
| \*\*Mean number of incontinence episodes per 24 hours (FAS‑I)\*\* | | | | | |
| n | 518 | 506 | 167 | 164 | 160 |
| Mean baseline | 2.93 | 2.98 | 2.97 | 3.31 | 2.86 |
| Mean change from baseline\\* | -0.92 | -1.49 | -1.00 | -1.48 | -1.10 |
| Mean difference from placebo\\* | -- | -0.57 | -- | -0.48 | -0.10 |
| 95% Confidence Interval | -- | (-0.81, -0.33) | -- | (-0.90, -0.06) | (-0.52, 0.32) |
| \*\*Mean number of micturitions per 24 hours (FAS)\*\* | | | | | |
| n | 704 | 688 | 238 | 240 | 231 |
| Mean baseline | 11.53 | 11.78 | 11.90 | 11.85 | 11.76 |
| Mean change from baseline\\* | -0.93 | -1.67 | -1.06 | -1.74 | -1.26 |
| Mean difference from placebo\\* | -- | -0.74 | -- | -0.68 | -0.20 |
| 95% Confidence Interval | -- | (-1.01, -0.47) | -- | (-1.12, -0.25) | (-0.64, 0.23) |
| \*\*Patients with prior OAB antimuscarinic therapy who discontinued due to insufficient effect\*\* | | | | | |
| \*\*Mean number of incontinence episodes per 24 hours (FAS‑I)\*\* | | | | | |
| n | 336 | 335 | 112 | 105 | 102 |
| Mean baseline | 3.03 | 2.94 | 3.15 | 3.50 | 2.63 |
| Mean change from baseline\\* | -0.86 | -1.56 | -0.87 | -1.63 | -0.93 |
| Mean difference from placebo\\* | -- | -0.70 | -- | -0.76 | -0.06 |
| 95% Confidence Interval | -- | (-1.01, -0.38) | -- | (-1.32, -0.19) | (-0.63, 0.50) |
| \*\*Mean number of micturitions per 24 hours (FAS)\*\* | | | | | |
| n | 466 | 464 | 159 | 160 | 155 |
| Mean baseline | 11.60 | 11.67 | 11.89 | 11.49 | 11.99 |
| Mean change from baseline\\* | -0.86 | -1.54 | -1.03 | -1.62 | -1.11 |
| Mean difference from placebo\\* | -- | -0.67 | -- | -0.59 | -0.08 |
| 95% Confidence Interval | -- | (-0.99, -0.36) | -- | (-1.15, -0.04) | (-0.64, 0.47) |
Pooled studies consisted of 046 (Europe/Australia), 047 (North America [NA]) and 074 (Europe/NA).
\\* Least squares mean adjusted for baseline, gender, study, subgroup, and subgroup by treatment interaction for Pooled Studies and least squares mean adjusted for baseline, gender, geographical region, subgroup, and subgroup by treatment interaction for Study 046.
FAS: Full analysis set, all randomised patients who took at least 1 dose of double blind study drug and who had a micturition measurement in the baseline diary and at least 1 post-baseline visit diary with a micturition measurement.
FAS-I: Subset of FAS who also had at least 1 incontinence episode in the baseline diary.
\*Neurogenic detrusor overactivity in paediatric patients\*
Efficacy of mirabegron tablets and oral suspension was evaluated in a 52-week, open-label, baseline-controlled, multicentre, dose titration study for the treatment of NDO in paediatric patients. Patients had a diagnosis of NDO with involuntary detrusor contractions with detrusor pressure increase greater than 15 cm H2O and performed clean intermittent catheterisation (CIC). Patients ≥ 35 kg received tablets and patients < 35 kg (or ≥ 35 kg but unable to tolerate tablets) received oral suspension. For all patients, mirabegron was administered orally once daily with food. The starting dose (PED25) was a 25 mg tablet or between 3‑6 ml of oral suspension (depending on patient weight). This dose was up‑titrated to PED50, a 50 mg tablet or between 6‑11 ml of oral suspension (depending on body weight). The dose titration period was a maximum of 8 weeks followed by a dose maintenance period of at least 52 weeks.
A total of 86 patients aged 3 to less than 18 years of age received mirabegron. Of these, 71 patients completed treatment through week 24 and 70 completed 52 weeks of treatment. A total of 68 patients had valid urodynamic measurements for evaluation of efficacy. The study population included 39 (45.3%) males and 47 (54.7%) females. The optimised maintenance dose within this study population included 94% of patients at the maximum dose, and 6% of patients at the starting dose.
The most common (in greater than 10% of all patients) background medical conditions related to NDO in children and adolescents included in the study were congenital central nervous system anomaly (54.5% and 48.4%, respectively), meningomyelocele (27.3% and 19.4%, respectively), and spina bifida (10.9% and 12.9%, respectively). In adolescents, 12.9% had a spinal cord injury.
The primary efficacy endpoint was change from baseline in maximum cystometric capacity (MCC) after 24 weeks of mirabegron treatment. Improvements in MCC were observed in all patient groups (see Table 6).
\*\*Table 6: Primary efficacy endpoint in paediatric patients with NDO\*\*
| | | |
| --- | --- | --- |
| \*\*Parameter\*\* | \*\*Children\*\* \*\*aged 3 to < 12 years\*\* \*\*(N=43)\\*\*\* \*\*Mean (SD)\*\* | \*\*Adolescents\*\* \*\*aged 12 to < 18 years\*\* \*\*(N=25)\\*\*\* \*\*Mean (SD)\*\* |
| \*\*Maximum cystometric capacity (ml)\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 158.6 (94.5) 230.7 (129.1) 72.0 (87.0) (45.2, 98.8) | 238.9 (99.1) 352.1 (125.2) 113.2 (82.9) (78.9, 147.4) |
\\* N is the number of patients who took at least one dose and provided valid values for MCC at baseline and week 24.
The secondary efficacy endpoints were change from baseline in bladder compliance, number of overactive detrusor contractions, detrusor pressure at end of bladder‑filling, bladder volume prior to first detrusor contraction, maximum catheterised urine volume per day, and number of leakage episodes per day after 24 weeks of mirabegron treatment (see Table 7).
\*\*Table 7: Secondary efficacy endpoints in paediatric patients with NDO\*\*
| | | |
| --- | --- | --- |
| \*\*Parameter\*\* | \*\*Children\*\* \*\*aged 3 to < 12 years\*\* \*\*(N=43)\\*\*\* \*\*Mean (SD)\*\* | \*\*Adolescents\*\* \*\*aged 12 to < 18 years\*\* \*\*(N=25)\\*\*\* \*\*Mean (SD)\*\* |
| \*\*Bladder compliance (ml/cm H2O)†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 14.5 (50.7) 29.6 (52.8) 14.6 (42.0) (-0.3, 29.5) | 11.0 (10.0) 23.8 (15.3) 13.5 (15.0) (6.7, 20.4) |
| \*\*Number of overactive detrusor contractions (> 15 cm H2O)†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 3.0 (3.8) 1.0 (2.2) -1.8 (4.1) (-3.2, -0.4) | 2.0 (2.9) 1.4 (2.3) -0.7 (3.8) (-2.4, 0.9) |
| \*\*Detrusor pressure (cm H2O) at end of bladder‑filling†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 42.2 (26.2) 25.6 (21.2) -18.1 (19.9) (-24.8, -11.3) | 38.6 (17.9) 27.8 (27.8) -13.1 (19.9) (-22.0, -4.3) |
| \*\*Bladder volume prior to first detrusor contraction (> 15 cm H2O)†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 115.8 (87.0) 207.9 (97.8) 93.1 (88.1) (64.1, 122.1) | 185.2 (121.2) 298.7 (144.4) 121.3 (159.8) (53.8, 188.8) |
| \*\*Maximum catheterised urine volume per day (ml)†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 300.1 (105.7) 345.9 (84.6) 44.2 (98.3) (13.2, 75.2) | 367.5 (119.0) 449.9 (146.6) 81.3 (117.7) (30.4, 132.3) |
| \*\*Number of leakage episodes per day†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 3.2 (3.7) 0.7 (1.2) -2.0 (3.2) (-3.2, -0.7) | 1.8 (1.7) 0.9 (1.2) -1.0 (1.1) (-1.5, -0.5) |
\\* N is the number of patients who took at least one dose and provided valid values for MCC at baseline and week 24.
† Number of patients (children/adolescents) with data available for both baseline and week 24; Bladder compliance: n=33/21; Number of overactive detrusor contractions: n=36/22; Detrusor pressure at end of bladder‑filling: n=36/22; Bladder volume prior to first detrusor contraction: n=38/24; Maximum catheterised urine volume per day: n=41/23; Number of leakage episodes per day: n=26/21.
Patient- or clinician-reported questionnaire endpoints included acceptability, change from baseline in the Pediatric Incontinence Questionnaire (PIN-Q), change from baseline in the Patient Global Impression of Severity Scale (PGI-S), and Clinician Global Impression of Change (CGI-C) (see Table 8).
\*\*Table 8: Patient- or clinician-reported questionnaire endpoints in paediatric patients with NDO\*\*
| | | |
| --- | --- | --- |
| \*\*Parameter\*\* | \*\*Children\*\* \*\*aged 3 to < 12 years\*\* \*\*(N=43)\\*\*\* \*\*Mean (SD)\*\* | \*\*Adolescents\*\* \*\*aged 12 to < 18 years\*\* \*\*(N=25)\\*\*\* \*\*Mean (SD)\*\* |
| \*\*Pediatric Incontinence Questionnaire (PIN-Q) score†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 30.8 (15.7) 30.6 (15.2) 2.0 (10.5) (-2.4, 6.4) | 29.4 (14.6) 25.2 (15.5) -4.9 (14.1) (-11.3, 1.5) |
| \*\*Total Patient Global Impression of Severity Scale (PGI-S) score†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 2.2 (0.8) 2.6 (0.8) 0.3 (1.2) (-0.1, 0.8) | 2.3 (0.9) 3.0 (0.7) 0.6 (1.0) (0.1, 1.0) |
| \*\*Total Clinician Global Impression of Change (CGI-C) at week 24, N (%)†\*\* | | |
| Very Much Improved Much Improved Minimally Improved No Change Minimally Worse Much Worse Very Much Worse | 6 (14.6%) 24 (58.5%) 6 (14.6%) 4 (9.8%) 1 (2.4%) 0 0 | 10 (41.7%) 7 (29.2%) 5 (20.8%) 1 (4.2%) 1 (4.2%) 0 0 |
\\* N is the number of patients who took at least one dose and provided valid values for MCC at baseline and week 24.
† Number of patients (children/adolescents) with data available for both baseline and week 24. PIN‑Q score: n=24/21, Total PGI-S score: n=25/22; Total CGI-C at week 24: n=41/24.
\*\*Paediatric population\*\*
The European Medicines Agency has waived the obligation to submit the results of studies with Mirabegron Astellas in all subsets of the paediatric population in “Treatment of idiopathic overactive bladder” (see section 4.2 for information on paediatric use).5.2 Pharmacokinetic properties
\*\*Absorption\*\*
\*Adults\*
After oral administration of mirabegron in healthy volunteers mirabegron is absorbed to reach peak plasma concentrations (Cmax) between 3 and 4 hours. The absolute bioavailability increased from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean Cmax and AUC increased more than dose proportionally over the dose range. In the overall adult population of males and females, a 2-fold increase in dose from 50 mg to 100 mg mirabegron increased Cmax and AUCtau by approximately 2.9- and 2.6‑fold, respectively, whereas a 4-fold increase in dose from 50 mg to 200 mg mirabegron increased Cmax and AUCtau by approximately 8.4- and 6.5-fold. Steady‑state concentrations are achieved within 7 days of once daily dosing with mirabegron. After once daily administration, plasma exposure of mirabegron at steady‑state is approximately double that seen after a single dose.
\*Paediatric population\*
The median Tmax of mirabegron following oral administration of a single dose of mirabegron tablets or oral suspension in patients under fed state was 4-5 hours. Population pharmacokinetic analysis predicted that the median Tmax of mirabegron tablets or oral suspension at steady-state was 3‑4 hours.
The bioavailability of the oral suspension formulation is lower than that of the tablet. The ratio of the population mean exposure (AUCtau) of the oral suspension to the tablet is approximately 45%.
\*\*Effect of food on absorption\*\*
\*Adults\*
Co-administration of a 50 mg tablet with a high-fat meal reduced mirabegron Cmax and AUC by 45% and 17%, respectively. A low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively. In the phase 3 studies, mirabegron was administered with or without food and demonstrated both safety and efficacy. Therefore, mirabegron can be taken with or without food at the recommended dose.
\*Paediatric population\*
The population pharmacokinetic model predicted that the patients receiving mirabegron in the fed state would have 44.7% of steady-state AUCtau relative to an equal dose administered in the fasted state. This value is consistent with the AUCinf results seen in the single-dose food effects studies for mirabegron. In the phase 3 paediatric study, mirabegron was administered with food and demonstrated both safety and efficacy. Dosing recommendations are based upon the exposures expected in the fed state. Therefore, in paediatric patients, mirabegron should be taken with food at the recommended dose.
\*\*Distribution\*\*
\*Adults\*
Mirabegron is extensively distributed. The volume of distribution at steady‑state (Vss) is approximately 1 670 l. Mirabegron is bound (approximately 71%) to human plasma proteins, and shows moderate affinity for albumin and alpha-1 acid glycoprotein. Mirabegron distributes to erythrocytes. \*In vitro\* erythrocyte concentrations of 14C-mirabegron were about 2-fold higher than in plasma.
\*Paediatric population\*
Mirabegron volume of distribution was relatively large and increased with increasing body weight in accordance with allometric principles based on population pharmacokinetic analysis. Age, sex and patient population had no impact on volume of distribution after accounting for potential differences in body weight.
\*\*Biotransformation\*\*
Mirabegron is metabolised via multiple pathways involving dealkylation, oxidation, (direct) glucuronidation, and amide hydrolysis. Mirabegron is the major circulating component following a single dose of 14C-mirabegron. Two major metabolites were observed in adult human plasma; both are phase 2 glucuronides representing 16% and 11% of total exposure. These metabolites are not pharmacologically active.
Based on \*in vitro\* studies, mirabegron is unlikely to inhibit the metabolism of co-administered medicinal products metabolised by the following cytochrome P450 enzymes: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP2E1 because mirabegron did not inhibit the activity of these enzymes at clinically relevant concentrations. Mirabegron did not induce CYP1A2 or CYP3A. Mirabegron is predicted not to cause clinically relevant inhibition of OCT-mediated drug transport.
Although \*in vitro\* studies suggest a role for CYP2D6 and CYP3A4 in the oxidative metabolism of mirabegron, \*in vivo\* results indicate that these isozymes play a limited role in the overall elimination. \*In vitro\* and \*ex vivo\* studies have shown the involvement from butyrylcholinesterase, UGT and possibly alcohol dehydrogenase (ADH) in the metabolism of mirabegron, in addition to CYP3A4 and CYP2D6.
\*CYP2D6 polymorphism\*
In healthy adult subjects who are genotypically poor metabolisers of CYP2D6 substrates (used as a surrogate for CYP2D6 inhibition), mean Cmax and AUCinf of a single 160 mg dose of a mirabegron IR formulation were 14% and 19% higher than in extensive metabolisers, indicating that CYP2D6 genetic polymorphism has minimal impact on the mean plasma exposure to mirabegron. Interaction of mirabegron with a known CYP2D6 inhibitor is not expected and was not studied. No dose adjustment is needed for mirabegron when administered with CYP2D6 inhibitors or in adult patients who are CYP2D6 poor metabolisers.
\*\*Elimination\*\*
\*Adults\*
Total body clearance (CLtot) from plasma is approximately 57 l/h. The terminal elimination half-life (t1/2) is approximately 50 hours. Renal clearance (CLR) is approximately 13 l/h, which corresponds to nearly 25% of CLtot. Renal elimination of mirabegron is primarily through active tubular secretion along with glomerular filtration. The urinary excretion of unchanged mirabegron is dose-dependent and ranges from approximately 6.0% after a daily dose of 25 mg to 12.2% after a daily dose of 100 mg. Following the administration of 160 mg 14C-mirabegron to healthy volunteers, approximately 55% of the radiolabel was recovered in the urine and 34% in the faeces. Unchanged mirabegron accounted for 45% of the urinary radioactivity, indicating the presence of metabolites. Unchanged mirabegron accounted for the majority of the faecal radioactivity.
\*Paediatric population\*
Mirabegron clearance was predicted to increase in patients with increasing body weight in accordance with allometric principles based on population pharmacokinetic analysis. The apparent clearance parameter was impacted significantly by dose, formulation, and food effects on relative bioavailability. Values of apparent clearance were highly variable but generally similar between children and adolescents, despite body weight differences, because of these effects on bioavailability.
\*\*Age\*\*
\*Adults\*
The Cmax and AUC of mirabegron and its metabolites following multiple oral doses in elderly volunteers (≥ 65 years) were similar to those in younger volunteers (18–45 years).
\*Paediatric population\*
In patients 3 to less than 18 years of age, age was not predicted to have any impact on key mirabegron pharmacokinetic parameters after accounting for differences in body weight. Models including age did not result in meaningful improvements to the paediatric population pharmacokinetic model, indicating that inclusion of body weight was sufficient to address differences in mirabegron pharmacokinetics due to age.
\*\*Gender\*\*
\*Adults\*
The Cmax and AUC are approximately 40% to 50% higher in females than in males. Gender differences in Cmax and AUC are attributed to differences in body weight and bioavailability.
\*Paediatric population\*
Gender has no meaningful impact on mirabegron pharmacokinetics in the paediatric population from 3 to less than 18 years of age.
\*\*Race\*\*
The pharmacokinetics of mirabegron in adults are not influenced by race.
\*\*Renal impairment\*\*
Following single dose administration of 100 mg mirabegron in adult volunteers with mild renal impairment (eGFR-MDRD 60 to 89 ml/min/1.73 m2), mean mirabegron Cmax and AUC were increased by 6% and 31% relative to adult volunteers with normal renal function. In adult volunteers with moderate renal impairment (eGFR-MDRD 30 to 59 ml/min/1.73 m2), Cmax and AUC were increased by 23% and 66%, respectively. In adult volunteers with severe renal impairment (eGFR-MDRD 15 to 29 ml/min/1.73 m2), mean Cmax and AUC values were 92% and 118% higher. Mirabegron has not been studied in patients with ESRD (eGFR < 15 ml/min/1.73 m2) or patients requiring haemodialysis.
\*\*Hepatic impairment\*\*
Following single dose administration of 100 mg mirabegron in adult volunteers with mild hepatic impairment (Child-Pugh Class A), mean mirabegron Cmax and AUC were increased by 9% and 19% relative to adult volunteers with normal hepatic function. In adult volunteers with moderate hepatic impairment (Child-Pugh Class B), mean Cmax and AUC values were 175% and 65% higher. Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).5.3 Preclinical safety data
Pre-clinical studies have identified target organs of toxicity that are consistent with clinical observations. Transient increases in liver enzymes and hepatocyte changes (necrosis and decrease in glycogen particles) were seen in rats and reduced plasma leptin levels were noted. An increase in heart rate was observed in rats, rabbits, dogs and monkeys. Genotoxicity and carcinogenicity studies have shown no genotoxic or carcinogenic potential \*in vivo\*.
Mirabegron had no discernible effect on gonadotropic or sex steroid hormone levels. In addition, no effects on fertility were seen at sub-lethal doses (human equivalent dose was 19‑fold higher than the maximum human recommended dose (MHRD)). The main findings in rabbit embryofetal development studies included malformations of the heart (dilated aorta, cardiomegaly) at systemic exposures 36‑fold higher than observed at the MHRD. In addition, malformations of the lung (absent accessory lobe of the lung) and increased post-implantation loss were observed in the rabbit at systemic exposures 14‑fold higher than observed at the MHRD, while in the rat reversible effects on ossification were noted (wavy ribs, delayed ossification, decreased number of ossified sternebrae, metacarpi or metatarsi) at systemic exposures 22-fold higher than observed at the MHRD. The observed embryofetal toxicity occurred at doses associated with maternal toxicity. The cardiovascular malformations observed in the rabbit were shown to be mediated via activation of the beta 1‑adrenoceptor.
The overall safety profile seen in juvenile rats was comparable to that observed in adult animals. Repeat dose safety studies performed in juvenile rats showed no effect on physical development or sexual maturation. Mirabegron administration from weaning through sexual maturation had no effect on mating ability, fertility or embryofoetal development. Mirabegron administration increased lipolysis and food consumption in juvenile rats.
Pharmacokinetic studies performed with radio-labelled mirabegron have shown that the parent compound and/or its metabolites are excreted in the milk of rats at levels that were approximately 1.7‑fold higher than plasma levels at 4 hours post administration (see section 4.6).
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
\*\*Core tablet\*\*
Macrogol 8000 and 2 000 000
Hydroxypropylcellulose
Butylhydroxytoluene
Magnesium stearate
\*\*Film coating\*\*
\*\*\*Mirabegron Astellas 25 mg prolonged-release tablets\*\*\*
Hypromellose 2910, 6 mPa.s
Macrogol 8000
Iron oxide yellow (E172)
Iron oxide red (E172)
\*\*\*Mirabegron Astellas 50 mg prolonged-release tablets\*\*\*
Hypromellose 2910, 6 mPa.s
Macrogol 8000
Iron oxide yellow (E172)6.2 Incompatibilities
Not applicable.6.3 Shelf life
3 years6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.6.5 Nature and contents of container
Alu-Alu blisters in cartons containing 10, 20, 30, 50, 60, 90, 100 or 200 tablets.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Instruction Content
- ## Composition
\*\*Mirabegron Astellas 25 mg prolonged-release tablets\*\*
Each tablet contains 25 mg of mirabegron.
\*\*Mirabegron Astellas 50 mg prolonged-release tablets\*\*
Each tablet contains 50 mg of mirabegron.
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Prolonged-release tablet.
\*\*Mirabegron Astellas 25 mg tablets\*\*
Oval, brown tablet, debossed with the company logo and “325” on the same side.
\*\*Mirabegron Astellas 50 mg tablets\*\*
Oval, yellow tablet, debossed with the company logo and “355” on the same side.
## Clinical Particulars
4.1 Therapeutic indications
\*\*Overactive bladder in adults\*\*
Mirabegron Astellas prolonged-release tablets are indicated for symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.
\*\*Neurogenic detrusor overactivity in the paediatric population\*\*
Mirabegron Astellas prolonged-release tablets are indicated for treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years.4.2 Posology and method of administration
\*\*Posology\*\*
\*\*\*Overactive bladder\*\*\*
\*Adults (including elderly patients)\*
The recommended dose is 50 mg once daily.
\*\*\*Neurogenic detrusor overactivity in the paediatric population\*\*\*
Paediatric patients 3 to less than 18 years of age with NDO may be administered Mirabegron Astellas prolonged-release tablets or Mirabegron Astellas granules for prolonged-release oral suspension based on the body weight of the patient. The prolonged-release tablets may be administered to patients weighing 35 kg or more; the granules for prolonged-release oral suspension are recommended for patients below 35 kg. Patients administered 6 ml oral suspension dose may be switched to 25 mg tablet dose and patients administered 10 ml oral suspension dose may be switched to 50 mg tablet dose.
The recommended starting dose of Mirabegron Astellas prolonged-release tablets is 25 mg once daily with food. If needed, the dose may be increased to a maximum dose of 50 mg once daily with food after 4 to 8 weeks. During long term therapy, patients should be periodically evaluated for treatment continuation and for potential dose adjustment, at least annually or more frequently if indicated.
Patients should be instructed to take any missed doses, unless more than 12 hours have passed since the missed dose. If more than 12 hours have passed, the missed dose can be skipped, and the next dose should be taken at the usual time.
\*\*Special populations\*\*
\*Renal and hepatic impairment\*
Mirabegron Astellas has not been studied in patients with end stage renal disease (ESRD) (estimated glomerular filtration rate (eGFR) < 15 ml/min/1.73 m2), patients requiring haemodialysis, or patients with severe hepatic impairment (Child-Pugh Class C) and, therefore, it is not recommended for use in these patient populations (see sections 4.4 and 5.2).
The following table provides the daily dosing recommendations for adult OAB patients with renal or hepatic impairment (see sections 4.4, 4.5 and 5.2).
\*\*Table 1: Daily dosing recommendations for adult OAB patients with renal or hepatic impairment\*\*
| | | |
| --- | --- | --- |
| \*\*Parameter\*\* | \*\*Classification\*\* | \*\*Dose\*\* \*\*(mg)\*\* |
| Renal impairment(1) | Mild/Moderate\\* | 50 |
| Severe\\*\\* | 25 |
| ESRD | Not recommended |
| Hepatic impairment(2) | Mild\\* | 50 |
| Moderate\\*\\* | 25 |
| Severe | Not recommended |
1. Mild/Moderate: eGFR 30 to 89 ml/min/1.73 m2; Severe: eGFR 15 to 29 ml/min/1.73 m2; ESRD: eGFR < 15 ml/min/1.73 m2.
2. Mild: Child-Pugh Class A; Moderate: Child-Pugh Class B; Severe: Child-Pugh Class C.
\\* In patients with mild to moderate renal impairment or mild hepatic impairment concomitantly receiving strong CYP3A inhibitors, the recommended dose is no more than 25 mg.
\\*\\* Not recommended for use in patients with severe renal impairment or moderate hepatic impairment concomitantly receiving strong CYP3A inhibitors.
The following table provides the daily dosing recommendations for paediatric NDO patients aged 3 to less than 18 years with renal or hepatic impairment weighing 35 kg or more (see sections 4.4 and 5.2).
\*\*Table 2: Daily dosing recommendations for paediatric NDO patients aged 3 to less than 18 years with renal or hepatic impairment weighing 35 kg or more\*\*
| | | | |
| --- | --- | --- | --- |
| \*\*Parameter\*\* | \*\*Classification\*\* | \*\*Starting dose\*\* \*\*(mg)\*\* | \*\*Maximum dose\*\* \*\*(mg)\*\* |
| Renal impairment(1) | Mild/Moderate\\* | 25 | 50 |
| Severe\\*\\* | 25 | 25 |
| ESRD | Not recommended | |
| Hepatic impairment(2) | Mild\\* | 25 | 50 |
| Moderate\\*\\* | 25 | 25 |
| Severe | Not recommended | |
1. Mild/Moderate: eGFR 30 to 89 ml/min/1.73 m2; Severe: eGFR 15 to 29 ml/min/1.73 m2;
ESRD: eGFR < 15 ml/min/1.73 m2. No dose adjustment is necessary for patients with mild to moderate renal impairment.
2. Mild: Child-Pugh Class A; Moderate: Child-Pugh Class B; Severe: Child-Pugh Class C.
\\* In patients with mild to moderate renal impairment or mild hepatic impairment concomitantly receiving strong CYP3A inhibitors, the recommended dose is no more than the starting dose.
\\*\\* Not recommended for use in patients with severe renal impairment or moderate hepatic impairment concomitantly receiving strong CYP3A inhibitors.
\*Gender\*
No dose adjustment is necessary according to gender.
\*Paediatric population\*
\*\*\*Overactive bladder\*\*\*
The safety and efficacy of mirabegron in children below 18 years of age with OAB have not yet been established. No data are available.
\*\*\*Neurogenic detrusor overactivity\*\*\*
The safety and efficacy of mirabegron in children below 3 years of age have not yet been established.
\*\*Method of administration\*\*
\*Overactive bladder in adults\*
The tablet is to be taken with liquids, swallowed whole, and is not to be chewed, divided, or crushed. It may be taken with or without food.
\*Neurogenic detrusor overactivity in the paediatric population\*
The tablet is to be taken with liquids, swallowed whole, and is not to be chewed, divided, or crushed. It should be taken with food.4.3 Contraindications
- Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
- Severe uncontrolled hypertension defined as systolic blood pressure ≥ 180 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg.4.4 Special warnings and precautions for use
\*\*Renal impairment\*\*
Mirabegron has not been studied in patients with ESRD (eGFR < 15 ml/min/1.73 m2) or patients requiring haemodialysis and, therefore, it is not recommended for use in this patient population. Data are limited in patients with severe renal impairment (eGFR 15 to 29 ml/min/1.73 m2); based on a pharmacokinetic study (see section 5.2) a dose of 25 mg once daily is recommended in this population. This medicinal product is not recommended for use in patients with severe renal impairment (eGFR 15 to 29 ml/min/1.73 m2) concomitantly receiving strong CYP3A inhibitors (see section 4.5).
\*\*Hepatic impairment\*\*
Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and, therefore, it is not recommended for use in this patient population. This medicinal product is not recommended for use in patients with moderate hepatic impairment (Child-Pugh B) concomitantly receiving strong CYP3A inhibitors (see section 4.5).
\*\*Hypertension\*\*
\*Overactive bladder in adults\*
Mirabegron can increase blood pressure. Blood pressure should be measured at baseline and periodically during treatment with mirabegron, especially in hypertensive patients.
Data are limited in patients with stage 2 hypertension (systolic blood pressure ≥ 160 mm Hg or diastolic blood pressure ≥ 100 mm Hg).
\*Neurogenic detrusor overactivity in the paediatric population\*
Mirabegron can increase blood pressure in paediatric patients. Blood pressure increases may be larger in children (3 to less than 12 years of age) than in adolescents (12 to less than 18 years of age). Blood pressure should be measured at baseline and periodically during treatment with mirabegron.
\*\*Patients with congenital or acquired QT prolongation\*\*
Mirabegron, at therapeutic doses, has not demonstrated clinically relevant QT prolongation in clinical studies (see section 5.1). However, since patients with a known history of QT prolongation or patients who are taking medicinal products known to prolong the QT interval were not included in these studies, the effects of mirabegron in these patients is unknown. Caution should be exercised when administering mirabegron in these patients.
\*\*Patients with bladder outlet obstruction and patients taking antimuscarinics medicinal products for OAB\*\*
Urinary retention in patients with bladder outlet obstruction (BOO) and in patients taking antimuscarinic medicinal products for the treatment of OAB has been reported in post‑marketing experience in patients taking mirabegron. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in patients treated with mirabegron; however, mirabegron should be administered with caution to patients with clinically significant BOO. Mirabegron should also be administered with caution to patients taking antimuscarinic medicinal products for the treatment of OAB.4.5 Interaction with other medicinal products and other forms of interaction
\*\*\*In vitro\* data\*\*
Mirabegron is transported and metabolised through multiple pathways. Mirabegron is a substrate for cytochrome P450 (CYP) 3A4, CYP2D6, butyrylcholinesterase, uridine diphospho‑glucuronosyltransferases (UGT), the efflux transporter P-glycoprotein (P-gp) and the influx organic cation transporters (OCT) OCT1, OCT2, and OCT3. Studies of mirabegron using human liver microsomes and recombinant human CYP enzymes showed that mirabegron is a moderate and time-dependent inhibitor of CYP2D6 and a weak inhibitor of CYP3A. Mirabegron inhibited P‑gp‑mediated drug transport at high concentrations.
\*\*\*In vivo\* data\*\*
\*Drug-drug interactions\*
The effect of co-administered medicinal products on the pharmacokinetics of mirabegron and the effect of mirabegron on the pharmacokinetics of other medicinal products was studied in single and multiple dose studies. Most drug‑drug interactions were studied using a dose of 100 mg mirabegron given as oral controlled absorption system (OCAS) tablets. Interaction studies of mirabegron with metoprolol and with metformin used mirabegron immediate‑release (IR) 160 mg.
Clinically relevant drug interactions between mirabegron and medicinal products that inhibit, induce or are a substrate for one of the CYP isozymes or transporters are not expected except for the inhibitory effect of mirabegron on the metabolism of CYP2D6 substrates.
\*Effect of enzyme inhibitors\*
Mirabegron exposure (AUC) was increased 1.8-fold in the presence of the strong inhibitor of CYP3A/P-gp ketoconazole in healthy volunteers. No dose-adjustment is needed when mirabegron is combined with inhibitors of CYP3A and/or P-gp. However, in patients with mild to moderate renal impairment (eGFR 30 to 89 ml/min/1.73 m2) or mild hepatic impairment (Child‑Pugh Class A) concomitantly receiving strong CYP3A inhibitors, such as itraconazole, ketoconazole, ritonavir and clarithromycin, the recommended dose is 25 mg once daily (see section 4.2). Mirabegron is not recommended in patients with severe renal impairment (eGFR 15 to 29 ml/min/1.73 m2) or patients with moderate hepatic impairment (Child‑Pugh Class B) concomitantly receiving strong CYP3A inhibitors (see sections 4.2 and 4.4).
\*Effect of enzyme inducers\*
Substances that are inducers of CYP3A or P-gp decrease the plasma concentrations of mirabegron. No dose adjustment is needed for mirabegron when administered with therapeutic doses of rifampicin or other CYP3A or P-gp inducers.
\*Effect of CYP2D6 polymorphism\*
CYP2D6 genetic polymorphism has minimal impact on the mean plasma exposure to mirabegron (see section 5.2). Interaction of mirabegron with a known CYP2D6 inhibitor is not expected and was not studied. No dose adjustment is needed for mirabegron when administered with CYP2D6 inhibitors or in patients who are CYP2D6 poor metabolisers.
\*Effect of mirabegron on CYP2D6 substrates\*
In healthy volunteers, the inhibitory potency of mirabegron towards CYP2D6 is moderate and the CYP2D6 activity recovers within 15 days after discontinuation of mirabegron. Multiple once daily dosing of mirabegron IR resulted in a 90% increase in Cmax and a 229% increase in AUC of a single dose of metoprolol. Multiple once daily dosing of mirabegron resulted in a 79% increase in Cmax and a 241% increase in AUC of a single dose of desipramine.
Caution is advised if mirabegron is co-administered with medicinal products with a narrow therapeutic index and significantly metabolised by CYP2D6, such as thioridazine, Type 1C antiarrhythmics (e.g., flecainide, propafenone) and tricyclic antidepressants (e.g., imipramine, desipramine). Caution is also advised if mirabegron is co-administered with CYP2D6 substrates that are individually dose titrated.
\*Effect of mirabegron on transporters\*
Mirabegron is a weak inhibitor of P-gp. Mirabegron increased Cmax and AUC by 29% and 27%, respectively, of the P-gp substrate digoxin in healthy volunteers. For patients who are initiating a combination of mirabegron and digoxin, the lowest dose for digoxin should be prescribed initially. Serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect. The potential for inhibition of P-gp by mirabegron should be considered when mirabegron is combined with sensitive P-gp substrates e.g. dabigatran.
\*Other interactions\*
No clinically relevant interactions have been observed when mirabegron was co-administered with therapeutic doses of solifenacin, tamsulosin, warfarin, metformin or a combined oral contraceptive medicinal product containing ethinylestradiol and levonorgestrel. Dose-adjustment is not recommended.
Increases in mirabegron exposure due to drug-drug interactions may be associated with increases in pulse rate.
\*\*Paediatric population\*\*
Interaction studies have only been performed in adults.4.6 Fertility, pregnancy and lactation
\*\*Women of childbearing potential\*\*
Mirabegron Astellas is not recommended in women of childbearing potential not using contraception.
\*\*Pregnancy\*\*
There are no or limited amount of data from the use of mirabegron in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Mirabegron Astellas is not recommended during pregnancy.
\*\*Breast-feeding\*\*
Mirabegron is excreted in the milk of rodents and therefore is predicted to be present in human milk (see section 5.3). No studies have been conducted to assess the impact of mirabegron on milk production in humans, its presence in human breast milk, or its effects on the breast-fed child.
Mirabegron Astellas should not be used during breast‑feeding.
\*\*Fertility\*\*
There were no treatment-related effects of mirabegron on fertility in animals (see section 5.3). The effect of mirabegron on human fertility has not been established.4.7 Effects on ability to drive and use machines
Mirabegron Astellas has no or negligible influence on the ability to drive and use machines.4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
The safety of mirabegron was evaluated in 8 433 adult patients with OAB, of which 5 648 received at least one dose of mirabegron in the phase 2/3 clinical program, and 622 patients received mirabegron for at least 1 year (365 days). In the three 12-week phase 3 double blind, placebo‑controlled studies, 88% of the patients completed treatment with this medicinal product, and 4% of the patients discontinued due to adverse events. Most adverse reactions were mild to moderate in severity.
The most common adverse reactions reported for adult patients treated with mirabegron 50 mg during the three 12-week phase 3 double blind, placebo-controlled studies are tachycardia and urinary tract infections. The frequency of tachycardia was 1.2% in patients receiving mirabegron 50 mg. Tachycardia led to discontinuation in 0.1% patients receiving mirabegron 50 mg. The frequency of urinary tract infections was 2.9% in patients receiving mirabegron 50 mg. Urinary tract infections led to discontinuation in none of the patients receiving mirabegron 50 mg. Serious adverse reactions included atrial fibrillation (0.2%).
Adverse reactions observed during the 1-year (long term) active controlled (muscarinic antagonist) study were similar in type and severity to those observed in the three 12-week phase 3 double blind, placebo‑controlled studies.
\*\*Tabulated list of adverse reactions\*\*
The table below reflects the adverse reactions observed with mirabegron in adults with OAB in the three 12-week phase 3 double blind, placebo‑controlled studies.
The frequency of adverse reactions is defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000) and not known (cannot be established from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
| | | | | | |
| --- | --- | --- | --- | --- | --- |
| \*\*MedDRA System organ class\*\* | \*\*Common\*\* | \*\*Uncommon\*\* | \*\*Rare\*\* | \*\*Very rare\*\* | \*\*Not known (cannot be estimated from the available data)\*\* |
| Infections and infestations | Urinary tract infection | Vaginal infection Cystitis | | | |
| Psychiatric disorders | | | | | Insomnia\\* Confusional state\\* |
| Nervous system disorders | Headache\\* Dizziness\\* | | | | |
| Eye disorders | | | Eyelid oedema | | |
| Cardiac disorders | Tachycardia | Palpitation Atrial fibrillation | | | |
| Vascular disorders | | | | Hypertensive crisis\\* | |
| Gastrointestinal disorders | Nausea\\* Constipation\\* Diarrhoea\\* | Dyspepsia Gastritis | Lip oedema | | |
| Hepatobiliary disorders | | GGT increased AST increased ALT increased | | | |
| Skin and subcutaneous tissue disorders | | Urticaria Rash Rash macular Rash papular Pruritus | Leukocytoclastic vasculitis Purpura Angioedema\\* | | |
| Musculoskeletal and connective tissue disorders | | Joint swelling | | | |
| Renal and urinary disorders | | | Urinary retention\\* | | |
| Reproductive system and breast disorders | | Vulvovaginal pruritus | | | |
| Investigations | | Blood pressure increased | | | |
\\*observed during post-marketing experience
\*\*Paediatric population\*\*
The safety of mirabegron tablets and oral suspension was evaluated in 86 paediatric patients aged 3 to less than 18 years with NDO in a 52-week, open-label, baseline-controlled, multicentre, dose titration study. The most commonly reported adverse reactions observed in the paediatric population were urinary tract infection, constipation, and nausea.
In the paediatric patients with NDO, no severe adverse reactions were reported.
Overall, the safety profile in children and adolescents is similar to that observed in adults.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Mirabegron has been administered to healthy adult volunteers at single doses up to 400 mg. At this dose, adverse events reported included palpitations (1 of 6 subjects) and increased pulse rate exceeding 100 beats per minute (bpm) (3 of 6 subjects). Multiple doses of mirabegron up to 300 mg daily for 10 days showed increases in pulse rate and systolic blood pressure when administered to healthy adult volunteers.
Treatment for overdose should be symptomatic and supportive. In the event of overdose, pulse rate, blood pressure, and ECG monitoring is recommended.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Urologicals, drugs for urinary frequency and incontinence, ATC code: G04BD12
\*\*Mechanism of action\*\*
Mirabegron is a potent and selective beta 3-adrenoceptor agonist. Mirabegron showed relaxation of bladder smooth muscle in rat and human isolated tissue, increased cyclic adenosine monophosphate (cAMP) concentrations in rat bladder tissue and showed a bladder relaxant effect in rat urinary bladder function models. Mirabegron increased mean voided volume per micturition and decreased the frequency of non-voiding contractions, without affecting voiding pressure, or residual urine in rat models of bladder overactivity. In a monkey model, mirabegron showed decreased voiding frequency. These results indicate that mirabegron enhances urine storage function by stimulating beta 3‑adrenoceptors in the bladder.
During the urine storage phase, when urine accumulates in the bladder, sympathetic nerve stimulation predominates. Noradrenaline is released from nerve terminals, leading predominantly to beta adrenoceptor activation in the bladder musculature, and hence bladder smooth muscle relaxation. During the urine voiding phase, the bladder is predominantly under parasympathetic nervous system control. Acetylcholine, released from pelvic nerve terminals, stimulates cholinergic M2 and M3 receptors, inducing bladder contraction. The activation of the M2 pathway also inhibits beta 3‑adrenoceptor induced increases in cAMP. Therefore, beta 3-adrenoceptor stimulation should not interfere with the voiding process. This was confirmed in rats with partial urethral obstruction, where mirabegron decreased the frequency of non-voiding contractions without affecting the voided volume per micturition, voiding pressure, or residual urine volume.
\*\*Pharmacodynamic effects\*\*
\*Urodynamics\*
Mirabegron at doses of 50 mg and 100 mg once daily for 12 weeks in men with lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) showed no effect on cystometry parameters and was safe and well tolerated. The effects of mirabegron on maximum flow rate and detrusor pressure at maximum flow rate were assessed in this urodynamic study consisting of 200 male patients with LUTS and BOO. Administration of mirabegron at doses of 50 mg and 100 mg once daily for 12 weeks did not adversely affect the maximum flow rate or detrusor pressure at maximum flow rate. In this study in male patients with LUTS/BOO, the adjusted mean (SE) change from baseline to end of treatment in post void residual volume (ml) was 0.55 (10.702), 17.89 (10.190), 30.77 (10.598) for the placebo, mirabegron 50 mg and mirabegron 100 mg treatment groups.
\*Effect on QT interval\*
Mirabegron at doses of 50 mg or 100 mg had no effect on the QT interval individually corrected for heart rate (QTcI interval) when evaluated either by sex or by the overall group.
A thorough QT (TQT) study (n=164 healthy male and n=153 healthy female volunteers with a mean age of 33 years) evaluated the effect of repeat oral dosing of mirabegron at the indicated dose (50 mg once daily) and two supra-therapeutic doses (100 and 200 mg once daily) on the QTcI interval. The supra-therapeutic doses represent approximately 2.6- and 6.5‑fold the exposure of the therapeutic dose, respectively. A single 400 mg dose of moxifloxacin was used as a positive control. Each dose level of mirabegron and moxifloxacin was evaluated in separate treatment arms each including placebo-control (parallel cross-over design). For both males and females administered mirabegron at 50 mg and 100 mg, the upper bound of the one-sided 95% confidence interval did not exceed 10 msec at any time point for the largest time-matched mean difference from placebo in the QTcI interval. In females administered mirabegron at the 50 mg dose, the mean difference from placebo on QTcI interval at 5 hours post dose was 3.67 msec (upper bound of the one-sided 95% CI 5.72 msec). In males, the difference was 2.89 msec (upper bound of the one-sided 95% CI 4.90 msec). At a mirabegron dose of 200 mg, the QTcI interval did not exceed 10 msec at any time point in males, while in females the upper bound of the one-sided 95% confidence interval did exceed 10 msec between 0.5–6 hours, with a maximum difference from placebo at 5 hours where the mean effect was 10.42 msec (upper bound of the one-sided 95% CI 13.44 msec). Results for QTcF and QTcIf were consistent with QTcI.
In this TQT study, mirabegron increased heart rate on ECG in a dose dependent manner across the 50 mg to 200 mg dose range examined. The maximum mean difference from placebo in heart rate ranged from 6.7 bpm with mirabegron 50 mg up to 17.3 bpm with mirabegron 200 mg in healthy subjects.
\*Effects on pulse rate and blood pressure in adult patients with OAB\*
In OAB patients (mean age of 59 years) across three 12-week phase 3 double blind, placebo‑controlled studies receiving mirabegron 50 mg once daily, an increase in mean difference from placebo of approximately 1 bpm for pulse rate and approximately 1 mm Hg or less in systolic blood pressure/diastolic blood pressure (SBP/DBP) was observed. Changes in pulse rate and blood pressure are reversible upon discontinuation of treatment.
\*Effects on blood pressure in paediatric patients with NDO\*
Mirabegron can increase blood pressure in paediatric patients. Blood pressure increases may be larger in children (3 to less than 12 years of age) than in adolescents (12 to less than 18 years of age). Blood pressure should be measured at baseline and periodically during treatment with mirabegron.
\*Effect on intraocular pressure (IOP)\*
Mirabegron 100 mg once daily did not increase IOP in healthy adult subjects after 56 days of treatment. In a phase 1 study assessing the effect of mirabegron on IOP using Goldmann applanation tonometry in 310 healthy subjects, a dose of mirabegron 100 mg was non-inferior to placebo for the primary endpoint of the treatment difference in mean change from baseline to day 56 in subject-average IOP; the upper bound of the two-sided 95% CI of the treatment difference between mirabegron 100 mg and placebo was 0.3 mm Hg.
\*\*Clinical efficacy and safety\*\*
\*Overactive bladder in adult patients\*
Efficacy of mirabegron was evaluated in three phase 3 randomised, double blind, placebo‑controlled, 12-week studies for the treatment of overactive bladder with symptoms of urgency and frequency with or without incontinence. Female (72%) and male (28%) patients with a mean age of 59 years (range 18 – 95 years) were included. The study population consisted of approximately 48% antimuscarinic treatment naïve patients as well as approximately 52% patients previously treated with antimuscarinic medicinal products. In one study, 495 patients received an active control (tolterodine prolonged release formulation).
The co-primary efficacy endpoints were (1) change from baseline to end of treatment in mean number of incontinence episodes per 24 hours and (2) change from baseline to end of treatment in mean number of micturitions per 24 hours based on a 3-day micturition diary. Mirabegron demonstrated statistically significant larger improvements compared to placebo for both co-primary endpoints as well as secondary endpoints (see Tables 3 and 4).
\*\*Table 3: Co-primary and selected secondary efficacy endpoints at end of treatment for pooled studies in adults\*\*
| | | |
| --- | --- | --- |
| \*\*Parameter\*\* | \*\*Pooled studies\*\* \*\*(046, 047, 074)\*\* | |
| \*\*Placebo\*\* | \*\*Mirabegron\*\* \*\*50 mg\*\* |
| \*\*Mean number of incontinence episodes per 24 hours (FAS‑I) (Co-primary)\*\* | | |
| n | 878 | 862 |
| Mean baseline | 2.73 | 2.71 |
| Mean change from baseline\\* | -1.10 | -1.49 |
| Mean difference from placebo\\* (95% CI) | -- | -0.40 (-0.58, -0.21) |
| p-value | -- | < 0.001‡ |
| \*\*Mean number of micturitions per 24 hours (FAS) (Co-primary)\*\* | | |
| n | 1 328 | 1 324 |
| Mean baseline | 11.58 | 11.70 |
| Mean change from baseline\\* | -1.20 | -1.75 |
| Mean difference from placebo\\* (95% CI) | -- | -0.55 (-0.75, -0.36) |
| p-value | -- | < 0.001‡ |
| \*\*Mean volume voided (ml) per micturition (FAS) (Secondary)\*\* | | |
| n | 1 328 | 1 322 |
| Mean baseline | 159.2 | 159.0 |
| Mean change from baseline\\* | 9.4 | 21.4 |
| Mean difference from placebo\\* (95% CI) | -- | 11.9 (8.3, 15.5) |
| p-value | -- | < 0.001‡ |
| \*\*Mean level of urgency (FAS) (Secondary)\*\* | | |
| n | 1 325 | 1 323 |
| Mean baseline | 2.39 | 2.42 |
| Mean change from baseline\\* | -0.15 | -0.26 |
| Mean difference from placebo\\* (95% CI) | -- | -0.11 (-0.16, -0.07) |
| p-value | -- | < 0.001‡ |
| \*\*Mean number of urgency incontinence episodes per 24 hours (FAS-I) (Secondary)\*\* | | |
| n | 858 | 834 |
| Mean baseline | 2.42 | 2.42 |
| Mean change from baseline\\* | -0.98 | -1.38 |
| Mean difference from placebo\\* (95% CI) | -- | -0.40 (-0.57, -0.23) |
| p-value | -- | < 0.001‡ |
| \*\*Mean number of episodes with urgency grades 3 or 4 per 24 hours (FAS) (Secondary)\*\* | | |
| n | 1 324 | 1 320 |
| Mean baseline | 5.61 | 5.80 |
| Mean change from baseline\\* | -1.29 | -1.93 |
| Mean difference from placebo\\* (95% CI) | -- | -0.64 (-0.89, -0.39) |
| p-value | -- | < 0.001‡ |
| \*\*Treatment satisfaction – visual analogue scale (FAS) (Secondary)\*\* | | |
| n | 1 195 | 1 189 |
| Mean baseline | 4.87 | 4.82 |
| Mean change from baseline\\* | 1.25 | 2.01 |
| Mean difference from placebo\\* (95% CI) | -- | 0.76 (0.52, 1.01) |
| p-value | -- | < 0.001† |
Pooled studies consisted of studies 046 (Europe/Australia), 047 (North America [NA]) and 074 (Europe/NA).
\\* Least squares mean adjusted for baseline, gender, and study.
† Statistically significantly superior compared to placebo at the 0.05 level without multiplicity adjustment.
‡ Statistically significantly superior compared to placebo at the 0.05 level with multiplicity adjustment.
FAS: Full analysis set, all randomised patients who took at least 1 dose of double blind study drug and who had a micturition measurement in the baseline diary and at least 1 post-baseline visit diary with a micturition measurement.
FAS-I: Subset of FAS who also had at least 1 incontinence episode in the baseline diary.
CI: Confidence Interval
\*\*Table 4: Co-primary and selected secondary efficacy endpoints at end of treatment for studies 046, 047 and 074 in adults\*\*
| | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| \*\*Parameter\*\* | \*\*Study 046\*\* | | | \*\*Study 047\*\* | | \*\*Study 074\*\* | |
| \*\*Placebo\*\* | \*\*Mirabegron 50 mg\*\* | \*\*Tolterodine ER 4 mg\*\* | \*\*Placebo\*\* | \*\*Mirabegron 50 mg\*\* | \*\*Placebo\*\* | \*\*Mirabegron 50 mg\*\* |
| \*\*Mean number of incontinence episodes per 24 hours (FAS‑I) (Co-primary)\*\* | | | | | | | |
| n | 291 | 293 | 300 | 325 | 312 | 262 | 257 |
| Mean baseline | 2.67 | 2.83 | 2.63 | 3.03 | 2.77 | 2.43 | 2.51 |
| Mean change from baseline\\* | -1.17 | -1.57 | -1.27 | -1.13 | -1.47 | -0.96 | -1.38 |
| Mean difference from placebo\\* | -- | -0.41 | -0.10 | -- | -0.34 | -- | -0.42 |
| 95% Confidence Interval | -- | (-0.72, ‑0.09) | (-0.42, 0.21) | -- | (-0.66, -0.03) | -- | (-0.76, -0.08) |
| p-value | -- | 0.003‡ | 0.11 | -- | 0.026‡ | -- | 0.001‡ |
| \*\*Mean number of micturitions per 24 hours (FAS) (Co-primary)\*\* | | | | | | | |
| n | 480 | 473 | 475 | 433 | 425 | 415 | 426 |
| Mean baseline | 11.71 | 11.65 | 11.55 | 11.51 | 11.80 | 11.48 | 11.66 |
| Mean change from baseline\\* | -1.34 | -1.93 | -1.59 | -1.05 | -1.66 | -1.18 | -1.60 |
| Mean difference from placebo\\* | -- | -0.60 | -0.25 | -- | -0.61 | -- | -0.42 |
| 95% Confidence Interval | -- | (-0.90, -0.29) | (-0.55, 0.06) | -- | (-0.98, -0.24) | -- | (-0.76, -0.08) |
| p-value | -- | < 0.001‡ | 0.11 | -- | 0.001‡ | -- | 0.015‡ |
| \*\*Mean volume voided (ml) per micturition (FAS) (Secondary)\*\* | | | | | | | |
| n | 480 | 472 | 475 | 433 | 424 | 415 | 426 |
| Mean baseline | 156.7 | 161.1 | 158.6 | 157.5 | 156.3 | 164.0 | 159.3 |
| Mean change from baseline\\* | 12.3 | 24.2 | 25.0 | 7.0 | 18.2 | 8.3 | 20.7 |
| Mean difference from placebo\\* | -- | 11.9 | 12.6 | -- | 11.1 | -- | 12.4 |
| 95% Confidence Interval | -- | (6.3, 17.4) | (7.1, 18.2) | -- | (4.4, 17.9) | -- | (6.3, 18.6) |
| p-value | -- | < 0.001‡ | < 0.001† | -- | 0.001‡ | -- | < 0.001‡ |
| \*\*Mean level of urgency (FAS) (Secondary)\*\* | | | | | | | |
| n | 480 | 472 | 473 | 432 | 425 | 413 | 426 |
| Mean baseline | 2.37 | 2.40 | 2.41 | 2.45 | 2.45 | 2.36 | 2.41 |
| Mean change from baseline\\* | -0.22 | -0.31 | -0.29 | -0.08 | -0.19 | -0.15 | -0.29 |
| Mean difference from placebo\\* | -- | -0.09 | -0.07 | -- | -0.11 | -- | -0.14 |
| 95% Confidence Interval | -- | (-0.17, -0.02) | (-0.15, 0.01) | -- | (-0.18, -0.04) | -- | (-0.22, -0.06) |
| p-value | -- | 0.018† | 0.085 | -- | 0.004† | -- | < 0.001§ |
| \*\*Mean number of urgency incontinence episodes per 24 hours (FAS-I) (Secondary)\*\* | | | | | | | |
| n | 283 | 286 | 289 | 319 | 297 | 256 | 251 |
| Mean baseline | 2.43 | 2.52 | 2.37 | 2.56 | 2.42 | 2.24 | 2.33 |
| Mean change from baseline\\* | -1.11 | -1.46 | -1.18 | -0.89 | -1.32 | -0.95 | -1.33 |
| Mean difference from placebo\\* | -- | -0.35 | -0.07 | -- | -0.43 | -- | -0.39 |
| 95% Confidence Interval | -- | (-0.65, -0.05) | (-0.38, 0.23) | -- | (-0.72, -0.15) | -- | (-0.69, -0.08) |
| p-value | -- | 0.003† | 0.26 | -- | 0.005† | -- | 0.002§ |
| \*\*Mean number of episodes with urgency grades 3 or 4 per 24 hours (FAS) (Secondary)\*\* | | | | | | | |
| n | 479 | 470 | 472 | 432 | 424 | 413 | 426 |
| Mean baseline | 5.78 | 5.72 | 5.79 | 5.61 | 5.90 | 5.42 | 5.80 |
| Mean change from baseline\\* | -1.65 | -2.25 | -2.07 | -0.82 | -1.57 | -1.35 | -1.94 |
| Mean difference from placebo\\* | -- | -0.60 | -0.42 | -- | -0.75 | -- | -0.59 |
| 95% Confidence Interval | -- | (-1.02, -0.18) | (-0.84, -0.00) | -- | (-1.20, -0.30) | -- | (-1.01, -0.16) |
| p-value | -- | 0.005† | 0.050† | -- | 0.001† | -- | 0.007§ |
| \*\*Treatment satisfaction – visual analogue scale (FAS) (Secondary)\*\* | | | | | | | |
| n | 428 | 414 | 425 | 390 | 387 | 377 | 388 |
| Mean baseline | 4.11 | 3.95 | 3.87 | 5.5 | 5.4 | 5.13 | 5.13 |
| Mean change from baseline\\* | 1.89 | 2.55 | 2.44 | 0.7 | 1.5 | 1.05 | 1.88 |
| Mean difference from placebo\\* | -- | 0.66 | 0.55 | -- | 0.8 | -- | 0.83 |
| 95% Confidence Interval | -- | (0.25, 1.07) | (0.14, 0.95) | -- | (0.4, 1.3) | -- | (0.41, 1.25) |
| p-value | -- | 0.001† | 0.008† | -- | < 0.001† | -- | < 0.001† |
\\* Least squares mean adjusted for baseline, gender and geographical region.
† Statistically significantly superior compared with placebo at the 0.05 level without multiplicity adjustment.
‡ Statistically significantly superior compared with placebo at the 0.05 level with multiplicity adjustment.
§ Not statistically significantly superior compared to placebo at the 0.05 level with multiplicity adjustment.
FAS: Full analysis set, all randomised patients who took at least 1 dose of double blind study drug and who had a micturition measurement in the baseline diary and at least 1 post-baseline visit diary with a micturition measurement.
FAS-I: Subset of FAS who also had at least 1 incontinence episode in the baseline diary.
Mirabegron 50 mg once daily was effective at the first measured time point of week 4, and efficacy was maintained throughout the 12-week treatment period. A randomised, active controlled, long term study demonstrated that efficacy was maintained throughout a 1-year treatment period.
\*Subjective improvement in health-related quality of life measurements\*
In the three 12-week phase 3 double blind, placebo‑controlled studies, treatment of the symptoms of OAB with mirabegron once daily resulted in a statistically significant improvement over placebo on the following health-related quality of life measures: treatment satisfaction and symptom bother.
\*Efficacy in patients with or without prior OAB antimuscarinic therapy\*
Efficacy was demonstrated in patients with and without prior OAB antimuscarinic therapy. In addition mirabegron showed efficacy in patients who previously discontinued OAB antimuscarinic therapy due to insufficient effect (see Table 5).
\*\*Table 5: Co-primary efficacy endpoints for adult patients with prior OAB antimuscarinic therapy\*\*
| | | | | | |
| --- | --- | --- | --- | --- | --- |
| \*\*Parameter\*\* | \*\*Pooled studies\*\* \*\*(046, 047, 074)\*\* | | \*\*Study 046\*\* | | |
| \*\*Placebo\*\* | \*\*Mirabegron 50 mg\*\* | \*\*Placebo\*\* | \*\*Mirabegron 50 mg\*\* | \*\*Tolterodine ER 4 mg\*\* |
| \*\*Patients with prior OAB antimuscarinic therapy\*\* | | | | | |
| \*\*Mean number of incontinence episodes per 24 hours (FAS‑I)\*\* | | | | | |
| n | 518 | 506 | 167 | 164 | 160 |
| Mean baseline | 2.93 | 2.98 | 2.97 | 3.31 | 2.86 |
| Mean change from baseline\\* | -0.92 | -1.49 | -1.00 | -1.48 | -1.10 |
| Mean difference from placebo\\* | -- | -0.57 | -- | -0.48 | -0.10 |
| 95% Confidence Interval | -- | (-0.81, -0.33) | -- | (-0.90, -0.06) | (-0.52, 0.32) |
| \*\*Mean number of micturitions per 24 hours (FAS)\*\* | | | | | |
| n | 704 | 688 | 238 | 240 | 231 |
| Mean baseline | 11.53 | 11.78 | 11.90 | 11.85 | 11.76 |
| Mean change from baseline\\* | -0.93 | -1.67 | -1.06 | -1.74 | -1.26 |
| Mean difference from placebo\\* | -- | -0.74 | -- | -0.68 | -0.20 |
| 95% Confidence Interval | -- | (-1.01, -0.47) | -- | (-1.12, -0.25) | (-0.64, 0.23) |
| \*\*Patients with prior OAB antimuscarinic therapy who discontinued due to insufficient effect\*\* | | | | | |
| \*\*Mean number of incontinence episodes per 24 hours (FAS‑I)\*\* | | | | | |
| n | 336 | 335 | 112 | 105 | 102 |
| Mean baseline | 3.03 | 2.94 | 3.15 | 3.50 | 2.63 |
| Mean change from baseline\\* | -0.86 | -1.56 | -0.87 | -1.63 | -0.93 |
| Mean difference from placebo\\* | -- | -0.70 | -- | -0.76 | -0.06 |
| 95% Confidence Interval | -- | (-1.01, -0.38) | -- | (-1.32, -0.19) | (-0.63, 0.50) |
| \*\*Mean number of micturitions per 24 hours (FAS)\*\* | | | | | |
| n | 466 | 464 | 159 | 160 | 155 |
| Mean baseline | 11.60 | 11.67 | 11.89 | 11.49 | 11.99 |
| Mean change from baseline\\* | -0.86 | -1.54 | -1.03 | -1.62 | -1.11 |
| Mean difference from placebo\\* | -- | -0.67 | -- | -0.59 | -0.08 |
| 95% Confidence Interval | -- | (-0.99, -0.36) | -- | (-1.15, -0.04) | (-0.64, 0.47) |
Pooled studies consisted of 046 (Europe/Australia), 047 (North America [NA]) and 074 (Europe/NA).
\\* Least squares mean adjusted for baseline, gender, study, subgroup, and subgroup by treatment interaction for Pooled Studies and least squares mean adjusted for baseline, gender, geographical region, subgroup, and subgroup by treatment interaction for Study 046.
FAS: Full analysis set, all randomised patients who took at least 1 dose of double blind study drug and who had a micturition measurement in the baseline diary and at least 1 post-baseline visit diary with a micturition measurement.
FAS-I: Subset of FAS who also had at least 1 incontinence episode in the baseline diary.
\*Neurogenic detrusor overactivity in paediatric patients\*
Efficacy of mirabegron tablets and oral suspension was evaluated in a 52-week, open-label, baseline-controlled, multicentre, dose titration study for the treatment of NDO in paediatric patients. Patients had a diagnosis of NDO with involuntary detrusor contractions with detrusor pressure increase greater than 15 cm H2O and performed clean intermittent catheterisation (CIC). Patients ≥ 35 kg received tablets and patients < 35 kg (or ≥ 35 kg but unable to tolerate tablets) received oral suspension. For all patients, mirabegron was administered orally once daily with food. The starting dose (PED25) was a 25 mg tablet or between 3‑6 ml of oral suspension (depending on patient weight). This dose was up‑titrated to PED50, a 50 mg tablet or between 6‑11 ml of oral suspension (depending on body weight). The dose titration period was a maximum of 8 weeks followed by a dose maintenance period of at least 52 weeks.
A total of 86 patients aged 3 to less than 18 years of age received mirabegron. Of these, 71 patients completed treatment through week 24 and 70 completed 52 weeks of treatment. A total of 68 patients had valid urodynamic measurements for evaluation of efficacy. The study population included 39 (45.3%) males and 47 (54.7%) females. The optimised maintenance dose within this study population included 94% of patients at the maximum dose, and 6% of patients at the starting dose.
The most common (in greater than 10% of all patients) background medical conditions related to NDO in children and adolescents included in the study were congenital central nervous system anomaly (54.5% and 48.4%, respectively), meningomyelocele (27.3% and 19.4%, respectively), and spina bifida (10.9% and 12.9%, respectively). In adolescents, 12.9% had a spinal cord injury.
The primary efficacy endpoint was change from baseline in maximum cystometric capacity (MCC) after 24 weeks of mirabegron treatment. Improvements in MCC were observed in all patient groups (see Table 6).
\*\*Table 6: Primary efficacy endpoint in paediatric patients with NDO\*\*
| | | |
| --- | --- | --- |
| \*\*Parameter\*\* | \*\*Children\*\* \*\*aged 3 to < 12 years\*\* \*\*(N=43)\\*\*\* \*\*Mean (SD)\*\* | \*\*Adolescents\*\* \*\*aged 12 to < 18 years\*\* \*\*(N=25)\\*\*\* \*\*Mean (SD)\*\* |
| \*\*Maximum cystometric capacity (ml)\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 158.6 (94.5) 230.7 (129.1) 72.0 (87.0) (45.2, 98.8) | 238.9 (99.1) 352.1 (125.2) 113.2 (82.9) (78.9, 147.4) |
\\* N is the number of patients who took at least one dose and provided valid values for MCC at baseline and week 24.
The secondary efficacy endpoints were change from baseline in bladder compliance, number of overactive detrusor contractions, detrusor pressure at end of bladder‑filling, bladder volume prior to first detrusor contraction, maximum catheterised urine volume per day, and number of leakage episodes per day after 24 weeks of mirabegron treatment (see Table 7).
\*\*Table 7: Secondary efficacy endpoints in paediatric patients with NDO\*\*
| | | |
| --- | --- | --- |
| \*\*Parameter\*\* | \*\*Children\*\* \*\*aged 3 to < 12 years\*\* \*\*(N=43)\\*\*\* \*\*Mean (SD)\*\* | \*\*Adolescents\*\* \*\*aged 12 to < 18 years\*\* \*\*(N=25)\\*\*\* \*\*Mean (SD)\*\* |
| \*\*Bladder compliance (ml/cm H2O)†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 14.5 (50.7) 29.6 (52.8) 14.6 (42.0) (-0.3, 29.5) | 11.0 (10.0) 23.8 (15.3) 13.5 (15.0) (6.7, 20.4) |
| \*\*Number of overactive detrusor contractions (> 15 cm H2O)†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 3.0 (3.8) 1.0 (2.2) -1.8 (4.1) (-3.2, -0.4) | 2.0 (2.9) 1.4 (2.3) -0.7 (3.8) (-2.4, 0.9) |
| \*\*Detrusor pressure (cm H2O) at end of bladder‑filling†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 42.2 (26.2) 25.6 (21.2) -18.1 (19.9) (-24.8, -11.3) | 38.6 (17.9) 27.8 (27.8) -13.1 (19.9) (-22.0, -4.3) |
| \*\*Bladder volume prior to first detrusor contraction (> 15 cm H2O)†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 115.8 (87.0) 207.9 (97.8) 93.1 (88.1) (64.1, 122.1) | 185.2 (121.2) 298.7 (144.4) 121.3 (159.8) (53.8, 188.8) |
| \*\*Maximum catheterised urine volume per day (ml)†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 300.1 (105.7) 345.9 (84.6) 44.2 (98.3) (13.2, 75.2) | 367.5 (119.0) 449.9 (146.6) 81.3 (117.7) (30.4, 132.3) |
| \*\*Number of leakage episodes per day†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 3.2 (3.7) 0.7 (1.2) -2.0 (3.2) (-3.2, -0.7) | 1.8 (1.7) 0.9 (1.2) -1.0 (1.1) (-1.5, -0.5) |
\\* N is the number of patients who took at least one dose and provided valid values for MCC at baseline and week 24.
† Number of patients (children/adolescents) with data available for both baseline and week 24; Bladder compliance: n=33/21; Number of overactive detrusor contractions: n=36/22; Detrusor pressure at end of bladder‑filling: n=36/22; Bladder volume prior to first detrusor contraction: n=38/24; Maximum catheterised urine volume per day: n=41/23; Number of leakage episodes per day: n=26/21.
Patient- or clinician-reported questionnaire endpoints included acceptability, change from baseline in the Pediatric Incontinence Questionnaire (PIN-Q), change from baseline in the Patient Global Impression of Severity Scale (PGI-S), and Clinician Global Impression of Change (CGI-C) (see Table 8).
\*\*Table 8: Patient- or clinician-reported questionnaire endpoints in paediatric patients with NDO\*\*
| | | |
| --- | --- | --- |
| \*\*Parameter\*\* | \*\*Children\*\* \*\*aged 3 to < 12 years\*\* \*\*(N=43)\\*\*\* \*\*Mean (SD)\*\* | \*\*Adolescents\*\* \*\*aged 12 to < 18 years\*\* \*\*(N=25)\\*\*\* \*\*Mean (SD)\*\* |
| \*\*Pediatric Incontinence Questionnaire (PIN-Q) score†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 30.8 (15.7) 30.6 (15.2) 2.0 (10.5) (-2.4, 6.4) | 29.4 (14.6) 25.2 (15.5) -4.9 (14.1) (-11.3, 1.5) |
| \*\*Total Patient Global Impression of Severity Scale (PGI-S) score†\*\* | | |
| Baseline Week 24 Change from baseline 95% Confidence Interval | 2.2 (0.8) 2.6 (0.8) 0.3 (1.2) (-0.1, 0.8) | 2.3 (0.9) 3.0 (0.7) 0.6 (1.0) (0.1, 1.0) |
| \*\*Total Clinician Global Impression of Change (CGI-C) at week 24, N (%)†\*\* | | |
| Very Much Improved Much Improved Minimally Improved No Change Minimally Worse Much Worse Very Much Worse | 6 (14.6%) 24 (58.5%) 6 (14.6%) 4 (9.8%) 1 (2.4%) 0 0 | 10 (41.7%) 7 (29.2%) 5 (20.8%) 1 (4.2%) 1 (4.2%) 0 0 |
\\* N is the number of patients who took at least one dose and provided valid values for MCC at baseline and week 24.
† Number of patients (children/adolescents) with data available for both baseline and week 24. PIN‑Q score: n=24/21, Total PGI-S score: n=25/22; Total CGI-C at week 24: n=41/24.
\*\*Paediatric population\*\*
The European Medicines Agency has waived the obligation to submit the results of studies with Mirabegron Astellas in all subsets of the paediatric population in “Treatment of idiopathic overactive bladder” (see section 4.2 for information on paediatric use).5.2 Pharmacokinetic properties
\*\*Absorption\*\*
\*Adults\*
After oral administration of mirabegron in healthy volunteers mirabegron is absorbed to reach peak plasma concentrations (Cmax) between 3 and 4 hours. The absolute bioavailability increased from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean Cmax and AUC increased more than dose proportionally over the dose range. In the overall adult population of males and females, a 2-fold increase in dose from 50 mg to 100 mg mirabegron increased Cmax and AUCtau by approximately 2.9- and 2.6‑fold, respectively, whereas a 4-fold increase in dose from 50 mg to 200 mg mirabegron increased Cmax and AUCtau by approximately 8.4- and 6.5-fold. Steady‑state concentrations are achieved within 7 days of once daily dosing with mirabegron. After once daily administration, plasma exposure of mirabegron at steady‑state is approximately double that seen after a single dose.
\*Paediatric population\*
The median Tmax of mirabegron following oral administration of a single dose of mirabegron tablets or oral suspension in patients under fed state was 4-5 hours. Population pharmacokinetic analysis predicted that the median Tmax of mirabegron tablets or oral suspension at steady-state was 3‑4 hours.
The bioavailability of the oral suspension formulation is lower than that of the tablet. The ratio of the population mean exposure (AUCtau) of the oral suspension to the tablet is approximately 45%.
\*\*Effect of food on absorption\*\*
\*Adults\*
Co-administration of a 50 mg tablet with a high-fat meal reduced mirabegron Cmax and AUC by 45% and 17%, respectively. A low-fat meal decreased mirabegron Cmax and AUC by 75% and 51%, respectively. In the phase 3 studies, mirabegron was administered with or without food and demonstrated both safety and efficacy. Therefore, mirabegron can be taken with or without food at the recommended dose.
\*Paediatric population\*
The population pharmacokinetic model predicted that the patients receiving mirabegron in the fed state would have 44.7% of steady-state AUCtau relative to an equal dose administered in the fasted state. This value is consistent with the AUCinf results seen in the single-dose food effects studies for mirabegron. In the phase 3 paediatric study, mirabegron was administered with food and demonstrated both safety and efficacy. Dosing recommendations are based upon the exposures expected in the fed state. Therefore, in paediatric patients, mirabegron should be taken with food at the recommended dose.
\*\*Distribution\*\*
\*Adults\*
Mirabegron is extensively distributed. The volume of distribution at steady‑state (Vss) is approximately 1 670 l. Mirabegron is bound (approximately 71%) to human plasma proteins, and shows moderate affinity for albumin and alpha-1 acid glycoprotein. Mirabegron distributes to erythrocytes. \*In vitro\* erythrocyte concentrations of 14C-mirabegron were about 2-fold higher than in plasma.
\*Paediatric population\*
Mirabegron volume of distribution was relatively large and increased with increasing body weight in accordance with allometric principles based on population pharmacokinetic analysis. Age, sex and patient population had no impact on volume of distribution after accounting for potential differences in body weight.
\*\*Biotransformation\*\*
Mirabegron is metabolised via multiple pathways involving dealkylation, oxidation, (direct) glucuronidation, and amide hydrolysis. Mirabegron is the major circulating component following a single dose of 14C-mirabegron. Two major metabolites were observed in adult human plasma; both are phase 2 glucuronides representing 16% and 11% of total exposure. These metabolites are not pharmacologically active.
Based on \*in vitro\* studies, mirabegron is unlikely to inhibit the metabolism of co-administered medicinal products metabolised by the following cytochrome P450 enzymes: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP2E1 because mirabegron did not inhibit the activity of these enzymes at clinically relevant concentrations. Mirabegron did not induce CYP1A2 or CYP3A. Mirabegron is predicted not to cause clinically relevant inhibition of OCT-mediated drug transport.
Although \*in vitro\* studies suggest a role for CYP2D6 and CYP3A4 in the oxidative metabolism of mirabegron, \*in vivo\* results indicate that these isozymes play a limited role in the overall elimination. \*In vitro\* and \*ex vivo\* studies have shown the involvement from butyrylcholinesterase, UGT and possibly alcohol dehydrogenase (ADH) in the metabolism of mirabegron, in addition to CYP3A4 and CYP2D6.
\*CYP2D6 polymorphism\*
In healthy adult subjects who are genotypically poor metabolisers of CYP2D6 substrates (used as a surrogate for CYP2D6 inhibition), mean Cmax and AUCinf of a single 160 mg dose of a mirabegron IR formulation were 14% and 19% higher than in extensive metabolisers, indicating that CYP2D6 genetic polymorphism has minimal impact on the mean plasma exposure to mirabegron. Interaction of mirabegron with a known CYP2D6 inhibitor is not expected and was not studied. No dose adjustment is needed for mirabegron when administered with CYP2D6 inhibitors or in adult patients who are CYP2D6 poor metabolisers.
\*\*Elimination\*\*
\*Adults\*
Total body clearance (CLtot) from plasma is approximately 57 l/h. The terminal elimination half-life (t1/2) is approximately 50 hours. Renal clearance (CLR) is approximately 13 l/h, which corresponds to nearly 25% of CLtot. Renal elimination of mirabegron is primarily through active tubular secretion along with glomerular filtration. The urinary excretion of unchanged mirabegron is dose-dependent and ranges from approximately 6.0% after a daily dose of 25 mg to 12.2% after a daily dose of 100 mg. Following the administration of 160 mg 14C-mirabegron to healthy volunteers, approximately 55% of the radiolabel was recovered in the urine and 34% in the faeces. Unchanged mirabegron accounted for 45% of the urinary radioactivity, indicating the presence of metabolites. Unchanged mirabegron accounted for the majority of the faecal radioactivity.
\*Paediatric population\*
Mirabegron clearance was predicted to increase in patients with increasing body weight in accordance with allometric principles based on population pharmacokinetic analysis. The apparent clearance parameter was impacted significantly by dose, formulation, and food effects on relative bioavailability. Values of apparent clearance were highly variable but generally similar between children and adolescents, despite body weight differences, because of these effects on bioavailability.
\*\*Age\*\*
\*Adults\*
The Cmax and AUC of mirabegron and its metabolites following multiple oral doses in elderly volunteers (≥ 65 years) were similar to those in younger volunteers (18–45 years).
\*Paediatric population\*
In patients 3 to less than 18 years of age, age was not predicted to have any impact on key mirabegron pharmacokinetic parameters after accounting for differences in body weight. Models including age did not result in meaningful improvements to the paediatric population pharmacokinetic model, indicating that inclusion of body weight was sufficient to address differences in mirabegron pharmacokinetics due to age.
\*\*Gender\*\*
\*Adults\*
The Cmax and AUC are approximately 40% to 50% higher in females than in males. Gender differences in Cmax and AUC are attributed to differences in body weight and bioavailability.
\*Paediatric population\*
Gender has no meaningful impact on mirabegron pharmacokinetics in the paediatric population from 3 to less than 18 years of age.
\*\*Race\*\*
The pharmacokinetics of mirabegron in adults are not influenced by race.
\*\*Renal impairment\*\*
Following single dose administration of 100 mg mirabegron in adult volunteers with mild renal impairment (eGFR-MDRD 60 to 89 ml/min/1.73 m2), mean mirabegron Cmax and AUC were increased by 6% and 31% relative to adult volunteers with normal renal function. In adult volunteers with moderate renal impairment (eGFR-MDRD 30 to 59 ml/min/1.73 m2), Cmax and AUC were increased by 23% and 66%, respectively. In adult volunteers with severe renal impairment (eGFR-MDRD 15 to 29 ml/min/1.73 m2), mean Cmax and AUC values were 92% and 118% higher. Mirabegron has not been studied in patients with ESRD (eGFR < 15 ml/min/1.73 m2) or patients requiring haemodialysis.
\*\*Hepatic impairment\*\*
Following single dose administration of 100 mg mirabegron in adult volunteers with mild hepatic impairment (Child-Pugh Class A), mean mirabegron Cmax and AUC were increased by 9% and 19% relative to adult volunteers with normal hepatic function. In adult volunteers with moderate hepatic impairment (Child-Pugh Class B), mean Cmax and AUC values were 175% and 65% higher. Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).5.3 Preclinical safety data
Pre-clinical studies have identified target organs of toxicity that are consistent with clinical observations. Transient increases in liver enzymes and hepatocyte changes (necrosis and decrease in glycogen particles) were seen in rats and reduced plasma leptin levels were noted. An increase in heart rate was observed in rats, rabbits, dogs and monkeys. Genotoxicity and carcinogenicity studies have shown no genotoxic or carcinogenic potential \*in vivo\*.
Mirabegron had no discernible effect on gonadotropic or sex steroid hormone levels. In addition, no effects on fertility were seen at sub-lethal doses (human equivalent dose was 19‑fold higher than the maximum human recommended dose (MHRD)). The main findings in rabbit embryofetal development studies included malformations of the heart (dilated aorta, cardiomegaly) at systemic exposures 36‑fold higher than observed at the MHRD. In addition, malformations of the lung (absent accessory lobe of the lung) and increased post-implantation loss were observed in the rabbit at systemic exposures 14‑fold higher than observed at the MHRD, while in the rat reversible effects on ossification were noted (wavy ribs, delayed ossification, decreased number of ossified sternebrae, metacarpi or metatarsi) at systemic exposures 22-fold higher than observed at the MHRD. The observed embryofetal toxicity occurred at doses associated with maternal toxicity. The cardiovascular malformations observed in the rabbit were shown to be mediated via activation of the beta 1‑adrenoceptor.
The overall safety profile seen in juvenile rats was comparable to that observed in adult animals. Repeat dose safety studies performed in juvenile rats showed no effect on physical development or sexual maturation. Mirabegron administration from weaning through sexual maturation had no effect on mating ability, fertility or embryofoetal development. Mirabegron administration increased lipolysis and food consumption in juvenile rats.
Pharmacokinetic studies performed with radio-labelled mirabegron have shown that the parent compound and/or its metabolites are excreted in the milk of rats at levels that were approximately 1.7‑fold higher than plasma levels at 4 hours post administration (see section 4.6).
## Pharmaceutical Particulars
6.1 List of excipients
\*\*Core tablet\*\*
Macrogol 8000 and 2 000 000
Hydroxypropylcellulose
Butylhydroxytoluene
Magnesium stearate
\*\*Film coating\*\*
\*\*\*Mirabegron Astellas 25 mg prolonged-release tablets\*\*\*
Hypromellose 2910, 6 mPa.s
Macrogol 8000
Iron oxide yellow (E172)
Iron oxide red (E172)
\*\*\*Mirabegron Astellas 50 mg prolonged-release tablets\*\*\*
Hypromellose 2910, 6 mPa.s
Macrogol 8000
Iron oxide yellow (E172)6.2 Incompatibilities
Not applicable.6.3 Shelf life
3 years6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.6.5 Nature and contents of container
Alu-Alu blisters in cartons containing 10, 20, 30, 50, 60, 90, 100 or 200 tablets.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
